Podcasts about Pfizer

This Special Episode on Atrial Fibrillation covers: Cardiology this Week: A concise summary of recent studies Atrial fibrillation burden: clinical relevance of a new outcome Pulsed field ablation: game changer? Drug treatment following atrial fibrillation ablation Spotlight: Holiday Heart Syndrome Host: Rick Grobbee Guests: Rick Grobbee, Konstantinos Koskinas, Jason Andrade, Arian Sultan, Michiel Rienstra Want to watch that special episode? Go to: https://esc365.escardio.org/event/2549 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Jason Andrade, Yasmina Bououdina, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Michiel Rienstra has declared to have potential conflicts of interest to report: consultancy fees from Bayer (OCEANIC-AF national PI) , InCarda Therapeutics (RESTORE-SR national PI), Novartis to the institution. Speaker fee from Daiichi-Sankyo, Pfizer to the institution. Unrestricted research grant from the Dutch Heart Foundation and is conducted in collaboration with and supported by the Dutch CardioVascular Alliance, 01-002-2022-0118 EmbRACE. Unrestricted research grant from ZonMW and the Dutch Heart Foundation; DECISION project 848090001. Unrestricted research grants from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation; RACE V (CVON 2014–9), RED-CVD (CVON2017-11). Unrestricted research grant from Top Sector Life Sciences & Health to the Dutch Heart Foundation (PPP Allowance; CVON-AI (2018B017). Unrestricted research grant from the European Union's Horizon 2020 research and innovation programme under grant agreement; EHRA-PATHS (945260). This research is funded by the Dutch Heart Foundation and is conducted in collaboration with and supported by the Dutch CardioVascular Alliance, 01 -002 -2022 -0118 EmbRACE.  Emma Svennberg has declared to have potential conflicts

Tara breaks down the historic battle within the Republican Party over the SAFE Act, exposing the Bush-era open borders leadership in the Senate and House. For the first time, technology and free speech are empowering grassroots conservatives to challenge entrenched party elites. From voter rolls to legislative battles, this episode explains why the fight could reshape American elections and sovereignty for decades.

Podcast del programa Imagen Empresarial transmitido originalmente el 17 de marzo del 2026. Conduce Rodrigo Pacheco Los entrevistados de hoy: Entrevista: José Roberto Solano Pérez, gerente de Análisis Económico, Cambiario y Bursátil en Monex Tema: ¿Cuál es el sentimiento de los inversionistas con las noticias más recientes de Medio Oriente? ¿Qué datos y eventos serán clave en la agenda de la semana? Entrevista: Juan Luis Morell, director general de Pfizer en México Tema: Acuerdo para fortalecer el desarrollo de vacunas en México

Linda Hill: Genius at Scale Linda Hill is the Wallace Brett Donham Professor of Business Administration and Faculty Chair of the Leadership Initiative at Harvard Business School. Globally recognized as a top leadership and innovation expert, Linda has been named by Thinkers50 as one of the world's top five management thinkers. She is the co-author, along with Emily Tedards and Jason Wild, of Genius at Scale: How Great Leaders Drive Innovation (Amazon, Bookshop)* We all want to think of ourselves as innovative, but it's often not easy to know exactly what that means in practice. In this conversation, Linda and I explore what her research shows that leaders do to drive innovation successfully – and how each of us can get just a bit better. Key Points Rather than coming up with a vision and asking people to follow it, innovation is about creating the culture and capabilities to create the future together. Innovation leadership shows up in three ways within organizations: the Architects, the Bridge Builders, and the Catalysts. Instead of setting the stage for themselves, innovative leaders set the stage for others. Often, we view horizontal relationships through the lens of organizational politics. The most effective innovation leaders view these relationships as leadership opportunities. Traditional team structures are a starting point, but not an ending point. Leaders at Mastercard, Pfizer, and Cleveland Clinic all brought in team members from both inside and outside the organization. Rather than thinking about a decision as final, it's helpful for innovation leaders to frame it as a “working hypothesis.” Resources Mentioned Genius at Scale: How Great Leaders Drive Innovation by Linda Hill, Emily Tedards, and Jason Wild (Amazon, Bookshop)* Interview Notes Download my interview notes in PDF format (free membership required). Related Episodes How to Build an Invincible Company, with Alex Osterwalder (episode 470) The Way Innovators Get Traction, with Tendayi Viki (episode 512) Doing Better Than Zero-Sum Thinking, with Renée Mauborgne (episode 641) Discover More Activate your free membership for full access to the entire library of interviews since 2011, searchable by topic. To accelerate your learning, uncover more inside Coaching for Leaders Plus.

Can an ICU nurse or a college mascot land a high-six-figure job at Pfizer or Stryker? In this episode of Medical Sales U, I sit down with three successful alumni to deconstruct the exact "pivot" strategies they used to reinvent their careers and land roles at the world's top medical companies.Whether you're a clinician looking for better work-life balance or a recent grad navigating the post-COVID job market, this deep dive reveals the networking secrets and interview "hooks" that actually work in 2026.What You'll Learn in This Episode:The "Network Outer Ring" Strategy: Why the person who hires you is likely already in your phone (and how to reach out without being awkward).From the "Shoe" to Pharma: How Corey leveraged being the Ohio State Mascot to prove his "sales DNA" to Pfizer.The 30-60-90 Day Rule: The specific document Viti used to stand out during the Stryker interview process.OR vs. Diagnostics: Why Ru transitioned from the operating room to Exact Sciences for better consistency and balance.The "3-Minute" Pitch: The exact answer that got a recruiter to say "Be ready for an interview on Tuesday."Timestamps:0:00 – Introduction: Meet the Columbus Crew1:45 – Ru's Story: From Finance & Fitness to Stryker Trauma3:12 – Why Diagnostics? The shift to Exact Sciences4:30 – The Networking Myth: Your "Who" is already there6:50 – Advice for the First 90 Days in a new role8:15 – Corey's Pivot: Transitioning from ICU Nursing to Pfizer10:15 – How to use your "Unique Hook" in an interview11:30 – The Pfizer Interview Process: "Why should I hire you?"14:00 – Viti's Journey: Pivoting from Pre-Med to MedTech16:20 – Mastering the 30-60-90 Day Proposal18:45 – Closing: How to join the Medical Sales U Community Resources Mentioned: The Power of Who by Bob Beaudine.

We've spoken with many guests about clinical and technological trends impacting healthcare providers, but less so about the trends on the business side of practicing medicine.  So on this episode, we're going to make up for that by spending our time with Dr. Alexander Vaccaro, an influential spine surgeon and president of one of the largest musculoskeletal practices in the U.S. -- Rothman Orthopaedic Institute -- which treats patients at over 40 locations in Pennsylvania, New Jersey, New York and Florida. While Dr. Vaccaro understands the desire for financial stability that's increasingly driving young physicians into the arms of hospital systems, he worries about what's being lost with the resulting decline in the number of independent practices.  “If you didn't have private practice advocating for the doctor, the insurance companies would bully the healthcare profession.” Join Raise the Line host Michael Carrese for a candid and lively conversation that also covers: How physician autonomy and entrepreneurship can drive innovation; The economic and policy forces reshaping private practice medicine; The role of research partnerships between private practices and universities. Mentioned in this episode:Rothman Orthopaedics If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

México desarrollará vacunas de ARN mensajeroCDMX busca garantizar presupuesto a programas socialesPeden a México garantizar presupuesto para refugios que atienden a mujeresMás información en nuestro Podcast

Six years ago on March 11th, 2020, the New Normal kicked off. The world we knew on, say, March 10th no longer existed. The way the politicians and pundits flood the public with war propaganda (as seen with the recent Iran strikes), the same tactics were used during the Covid years. Instead of a Middle Easterner, the enemy we needed to fight was a spooky, invisible virus.   In this annual episode, Tony Mazur takes a look back at the insanity that was 2020, as well as 2021 when the vaccine mandates and subsequent intimidation and coercion techniques were unleashed. Has there been "hell to pay," as Rand Paul suggested with accountability towards Dr. Anthony Fauci? Nope. Even though Fauci, Bill Gates, and even Jeffrey Epstein were hip to plans surrounding a potential pandemic. Mothers lost their babies in Pfizer trials. Athletes lost out on the big leagues and big money due to vaccine injury. And here in March 2026, no one has or will be held accountable. If anything, people will be miffed at Tony for still discussing Covid after all these years.   Be sure to subscribe to Tony's Patreon. $3 gets you just audio, $5 gets video AND audio, and $10 has all of the above, as well as bonus podcasts per week. Visit Patreon.com/TonyMazur. Tony is also on Rumble! Go find his video podcasts over there for free.   Cover art for the Check Your Brain podcast is by Eric C. Fischer. If you need terrific graphic design work done, contact Eric at illstr8r@gmail.com.

In this episode of Let's Combinate, Subhi Saadeh speaks with Jen Riter about analytical method validation for drug device combination products. The discussion explores how traditional drug analytical validation under ICH Q2 differs from validating functional and mechanical performance methods used for combination products. These methods often require an engineering mindset that incorporates measurement system analysis (MSA), gage R&R studies, and the use of fabricated surrogate standards when devices cannot be reused for testing.They also discuss platform test methods and how standards such as ISO 11040 and other ISO references can serve as starting points for method development. The conversation touches on the evolving alignment between ISO based device methods and pharmacopeial expectations such as USP . The episode also covers make vs buy testing decisions, when to outsource specialized testing such as CCIT and extractables and leachables, and how sponsors manage oversight of contract testing laboratories.Timestamps00:00 Welcome and Guest Introduction00:53 ICH Q2 vs MSA Mindset Shift04:37 Surrogate Standards for Mechanical Testing11:12 Platform Methods and ISO 1104015:14 ISO vs USP Verification Debate20:06 Outsourcing Analytical Testing Strategy24:07 Choosing the Right Test Lab26:20 Sponsor Oversight of Contract Labs30:09 Wrap UpAbout Jen RiterJen Riter is an analytical testing and laboratory leader with nearly three decades of experience working in pharmaceutical packaging, drug delivery systems, and combination products. She has held leadership roles at West Pharmaceutical Services and Kindeva Drug Delivery, where her work has focused on analytical method development, validation, and testing strategies for drug delivery systems and injectable combination products. She is also a contributor to the Combination Products Handbook, where she authored a chapter on analytical testing and method validation for combination products.About Subhi SaadehSubhi Saadeh is the Founder and Principal of Let's Combinate BioWorks, where he helps companies close the gaps between drug and device development, quality systems, and regulatory expectations. He is a Certified Quality Auditor and ISO 13485 Lead Auditor with leadership experience at Baxter, Pfizer, and Gilead Sciences including responsibility for management and oversight of assemble label pack sites and working with device primary, secondary and tertiary packaging suppliers. Subhi previously chaired the Combination Product Working Group for Rx-360, served as International Committee Chair for the Combination Products Coalition, and served on AAMI's Combination Products Committee. He also hosts the Let's Combinate podcast and is a writer and speaker on quality at the intersection of drugs and devices.

Sometimes the most powerful guidance arrives quietly through intuition, synchronicity, and reflection. Join Amy and Dr. Judi Neal, the Founder of Edgewalkers, as they give into the Edgewalker framework and the creation of the Edgewalker card deck, a tool designed to help people navigate change while staying connected to purpose and inner wisdom. Together they discuss how symbols, affirmations, and reflective practices can reveal insight in unexpected ways. From leadership development to spiritual awareness, the discussion highlights how intuitive tools can help people reconnect with their gifts, bring creativity into their work, and move forward with clarity even in uncertain times. The message is simple yet powerful: when people learn to listen to both practical wisdom and deeper intuition, they become the kind of leaders the future needs.Key Takeaways:1. The Edgewalker Mindset – Discover the qualities that define people who bridge practical leadership and spiritual awareness in times of change.2. How The Card Deck Was Created – Learn how intention, creativity, and emerging technology combined to bring the Edgewalker deck into the world.3. The Role Of Synchronicity – Explore why seemingly random messages often arrive at exactly the right moment for reflection or decision making.4. Symbolism As A Source Of Insight – Understand how visual symbols and archetypes can activate intuition and deeper awareness.5. Leadership In Uncertain Times – Reflect on how spiritual grounding and community can help leaders navigate disruption and uncertainty.6. Living Your Gifts With Purpose – See why using your gifts in service to both your life and the world creates sustainable passion and energy.To purchase your own copy of the Edgewalker Card Deck visit https://createmagicatwork.net/shop/ols/products/the-edgewalker-card-deckAbout the Guest:Dr. Judi Neal is the Founder, Chairman, and CEO of Edgewalkers International. She was the founding director of the Tyson Center for Faith and Spirituality in the Workplace at the Sam M. Walton College of Business, University of Arkansas. Judi is recognized as an expert on spirituality in the workplace and speaks and consults internationally. She received her Ph.D. from Yale in Organizational Behavior. In 1988 Judi began teaching management at the University of New Haven. She focused her research on business leaders who have a strong commitment to their faith and spirituality, and began studying how they bridged the spiritual world and the material world of business. That led to her research on people she calls “Edgewalkers.” Judi was a co-founder of the Management, Spirituality and Religion Interest Group at the Academy of Management, as well as co-founder of the Journal of Management, Spirituality and Religion, and the International Association of Management, Spirituality and Religion. She has published widely in the field, and is a popular and inspiring international speaker. She has consulted with major organizations such as Pfizer and General Electric as well as with small entrepreneurial companies and with non-profits.https://edgewalkers.org/https://www.linkedin.com/groups/14345722/https://www.instagram.com/edgewalkersAbout Amy:Amy Lynn Durham, known by her clients as the Corporate Mystic, is the founder of the Executive Coaching Firm, Create Magic At Work®, where they help leaders build workplaces rooted in creativity, collaboration, and fulfillment. A former corporate executive turned Executive Coach, Amy blends practical leadership strategies with spiritual intelligence to unlock human potential at work.She's a certified Executive Coach through UC Berkeley & the International Coaching Federation (ICF) In addition, Amy holds coaching certifications in Spiritual Intelligence (SQ21), the Edgewalker Profile, and the Archetypes of Change . In addition to being the host of the Create Magic At Work® podcast, Amy is the author of Create Magic At Work®, Creating Career Magic: A Daily Prompt Journal and the founder of Magic Thread Media™. Through her work, she inspires intentional leadership for thriving workplaces and lives where “magic” becomes reality.Connect with Amy:https://createmagicatwork.net/https://www.linkedin.com/company/create-magic-at-workhttps://www.facebook.com/112951637095427https://www.instagram.com/createmagicatworkhttps://www.youtube.com/channel/UCnEm4h3fUgaq8qgvZpz6dGgThanks for listening!Thanks so much for listening to our podcast! If you enjoyed this episode and think that others could benefit from listening, please share it using the social media buttons on this page.Do you have some feedback or questions about this episode? Leave a comment in the section below!Subscribe to the podcastIf you would like to get automatic updates of new podcast episodes, you can follow the podcast on Apple Podcasts or your favorite podcast app.Leave us an Apple Podcasts reviewRatings and reviews from our listeners are extremely valuable to us and greatly appreciated. They help our podcast rank higher on Apple Podcasts, which exposes our show to more awesome listeners like you. If you are enjoying the show, please leave us a review on Apple Podcasts.Mentioned in this episode:This show was brought to you in part by the Magic Thread Media Network. To learn more visit: https://magicthreadmedia.com/

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über einen völlig verrückten Wochenstart an den Märkten, einen durchwachsenen Börsengang in Frankfurt und einen deutschen Maschinenbauer mit Zoll-Resilienz. Außerdem geht es um Alphabet, Amazon, American Airlines, Amgen, Apple, Barrick Gold, Biontech, Caterpillar, Chevron, Cisco, Coherent, ConocoPhillips, Corteva, CSG, Deere, Delta Air Lines, Echostar, Eli Lilly, ExxonMobil, Freeport-McMoRan, Gabler Group, Gea, HP Enterprise, Intuitive Surgical, Johnson & Johnson, Live Nation Entertainment, Lumentum, Meta, Microsoft, Mosaic, Newmont, Nordisk, Novo Nordisk, Nuccor, Nvidia, Occidental, Oracle, Pfizer, Powerus, Southern Copper, Southwest, T-Mobile, ThyssenKrupp, TKMS, United Airlines, Verizon, Vertiv, VW, Walmart. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Mariano García-Valiño is a healthcare technology entrepreneur and author who has founded and led multiple companies at the intersection of healthcare, software, and data, most recently as Founder, Chief Engineer, and CEO of Axenya, a digital health platform recognized by Newsweek and Galen Growth among the world's leading health-tech innovators. He has driven the growth, expansion, and successful exits of several major firms, including Bausch + Lomb (approx. 9B USD sale in 2013), Grupo Biotoscana (IPO around 1B USD in 2017), and M8 Pharmaceuticals (approx. 250M USD sale in 2023), and has also invested in and advised other healthcare and pharmaceutical ventures across Latin America.​Earlier in his career, García-Valiño held senior roles in global organizations such as Advent, Warburg Pincus, Aqua Capital, Pfizer, Lilly, and McKinsey, gaining broad international experience across the United States, Latin America, and Europe. He is the author of “INEDIBLE: How to Build the Modern, Tech-Enabled, Healthcare Experience,” a book that became a #1 Amazon best seller and Hot New Release in the United States, where he examines why healthcare has lagged in digital transformation and outlines how technology can enable more intelligent, connected, and preventive care.​In parallel to his business career, he is an experimental art photographer whose abstract work, exploring hyperobjects, entropy, and inter-temporality, has been exhibited in contemporary galleries and is held in private and museum collections in Argentina, Uruguay, Brazil, Colombia, Spain, and the United States. García-Valiño holds an Engineering degree from the Universidad de Buenos Aires, a Photography PC from Cornell University, and an MBA from Harvard Business School, where he studied as a Fulbright Scholar.LinkedIN page: https://www.linkedin.com/in/mgarciavalino/Book: https://a.co/d/05gLJOHHPhotography: https://mgarciavalino.com/Company: https://axenya.com/Connect and tag me at:https://www.instagram.com/realangelabradford/You can subscribe to my YouTube Channel herehttps://www.youtube.com/channel/UCDU9L55higX03TQgq1IT_qQFeel free to leave a review on all major platforms to help get the word out and change more lives!

Dr. Pedro Barata and Dr. Kathryn Schmitz discuss evidence-based exercise oncology programs, how to incorporate exercise into cancer care and connect the right patient to the right program, and ultimately build a culture of exercise in oncology. TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast series from ASCO that features compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist and a clinical trialist at the University Hospital Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also happy to serve as a deputy editor for the ASCO Educational Book. Today, we'll be talking about exercise. We have plenty of evidence that exercise benefits symptoms, improves the quality of life of patients, and actually has been shown to reduce risk of recurrence of cancer but also improve survival. And I think that's increasingly clear as data emerges. Today, I'm delighted to be speaking to Dr. Kathryn Schmitz. She's a leading expert on integrating exercise into cancer care. Dr. Schmitz serves as the deputy director of the University of Pittsburgh Hillman Cancer Center and also a professor of hematology-oncology at University of Pittsburgh Medical School. She's the senior author of a fantastic article in the ASCO Educational Book that's titled "Implementation Science as the Secret Sauce for Integrating Exercise Screening and Triage Pathways in Oncology." She also led a really compelling piece that just got published in JCO titled "If Exercise Were a Pill, We'd All Prescribe It to Patients With Cancer. But It's Not" So I'm thrilled to have Dr. Schmitz joining us today and helping us explore evidence-based exercise oncology programs, how to incorporate exercise into cancer care, and also how to connect the right patient to the right program.  So with that, welcome, Dr. Schmitz. Thank you so much for taking the time to chat with us. Dr. Kathryn Schmitz: Thank you for the opportunity. Dr. Pedro Barata: One of the highlights of ASCO last year and practice changing, in my opinion, data out of The New England [Journal of Medicine] is called the CHALLENGE trial. It did provide high level evidence that a structured, supervised exercise program could improve both disease-free survival and overall survival. This is a study in the GI world, but I think it got a lot of attraction and attention beyond the GI world, across solid tumors, really. Could you give us a little brief recap of that trial and what have you seen as being the impact in practices around oncology? Dr. Kathryn Schmitz: So, CHALLENGE was very exciting. Prior to CHALLENGE, there were any number of observational studies that indicated that there was a relationship between being more physically active and reduced recurrence and improved overall survival for colon cancer in particular. You know, notably, in 2006, Jeff Meyerhardt published two papers in the same journal, of the same issue of JCO, showing very, very similar data from two very large studies. And those were studies number five and six in this area. You know, there's a lot of evidence observationally, but we don't generally change clinical practice on the basis of observational data. So, we were all waiting very impatiently for the results of the CHALLENGE trial. And it was very exciting to be in the front row when the results were reported out and to be part of the group with a standing ovation for the authors when it was presented. To summarize, 889 colon cancer patients, stage II and III, were randomized into either a structured exercise program or a health education control comparison group and followed for an average of 7.9 years. And the structured exercise group had a 27% reduced risk of recurrence and a 38% improvement in overall survival. One of the things that's really notable about this is that what we typically expect is that when we go from the observational literature to the clinical trial literature, that we expect effects to go down. We expect to see a larger effect in the observational than in the RCT land, and that did not happen here. We actually see an effect that matches what we've seen in observational literature, which is really, really exciting.  And, you know, one of the reasons why this has been so exciting across not just GI but other cancers is the notable finding of a reduced risk of second primaries. So, they only observed two breast cancer second primaries in the treatment group and 12 in the comparison group. And overall, they reduced the second primaries occurrence, hazard ratio was 0.5, a 50% reduction of second primaries, which is just remarkable. It really got everybody very, very excited. And now the big question, of course, is, all right, how do I do this? How do I make this happen?  The thing to note is that what they did in CHALLENGE is probably not doable in your clinic tomorrow. It's a heavy intervention. The number of touchpoints from staff is extensive, and the amount of time needed from staff for the coaching and supervised exercise is extensive as well. The criteria for getting people into the program required that people go through a series of blood tests and imaging tests that would just simply not be possible for the average community oncologist. So I'm guessing that you're going to ask me some questions about how we do this. Dr. Pedro Barata: Right. That's a fantastic segue. That's exactly right. Walk us through maybe starting by, what does that mean? Dr. Kathryn Schmitz: The first thing to say is I have to go back to the observational literature. And the observational literature shows really compellingly that we have a strong reduction of breast cancer recurrence and mortality from being more physically active, prostate cancer recurrence and mortality, and colon cancer recurrence and mortality. I find it very difficult to believe in this day and age, in our current environment, if you will, that we are ever going to have the equivalent of CHALLENGE for prostate or for breast cancer. There is an ongoing study in prostate that's led by some Australian researchers, but I just don't think that it's likely that we're going to mount something similar for another tumor site. We have tremendous correlative data that indicates that there are a number of biomarkers and biological pathways through which breast, colon, and prostate cancer would be reduced in recurrence if people were more physically active. And so, there is really, from my thinking, very little to state that it would be just a colon cancer effect. And so this is something we probably can enact in more than just the colon cancer community, overall, which is great news, and it makes it easier for us to be able to enact this type of programming. Dr. Pedro Barata: One of the things that comes up perhaps often is, if I were the leader of the cancer center and were to incentivize the different care teams to implement an exercise program at each level: GI team, GU, breast, thoracic, etc. How do we do that? Dr. Kathryn Schmitz: So, I want to give you an analogy. You're a medical oncologist, and you prescribe your patients chemotherapy. Now, just imagine, if you will, what would happen and how likely it would be for your patients to get chemotherapy if there was no chemoinfusion suite. If the chemoinfusion suite disappeared tomorrow and you were to tell your patients, "Go get some chemotherapy," what proportion of those patients do you think would go find all of the equipment necessary and all of the drugs necessary and understand how to dose the chemotherapy for themselves and get that all done? Very few people would do it. So with exercise, why would we be surprised then that our patients don't actually do a whole lot if we just simply tell them to go get some exercise? Exercise is a medicine. It is effective like a medicine. We've shown this through the CHALLENGE trial and many other correlative studies and an ocean of observational data as well. So the question is, how do we build the infrastructure that is necessary in order for your patients to do this? So the very first thing that has to happen is that somebody has to tell the patient to exercise. We currently do not have a culture of exercise in oncology. We do in heart disease. If you ask the average person on the street, "Is exercise good for your heart?" Anybody with an eighth-grade education is going to say, "Yes, of course," because the American Heart Association has done an amazing job telling everybody that exercise is good for your heart. But what has ASCO done, frankly? Can I be that bold? What has ASCO done to tell patients that they should be exercising during and after their cancer treatment? I'm not sure that I know more than a guideline. There is a guideline, and that's great. And the guideline is very helpful, but I'm not sure that patients know that there's a guideline. In fact, I can tell you that patients don't know that there is a guideline. So, you know, making sure that there's a paradigm shift in the country that says exercise is good for patients during and after their cancer treatment is the first step. The second step is getting a medical professional to say something to the patient about the exercise. And I'm very careful with the two words that I just chose: medical professional. I do understand medical oncologists are very busy. I understand that there's a whole lot to say in that 15 minutes when you're with the patient. And so maybe it isn't the medical oncologist. Ideally, it would be, but I get it that there's limited time. So it could be a nurse practitioner, it could be a nurse, there could be a social worker, it could be somebody else on the team that says, "Hey, you know, we want you to do an exercise program. We want to connect you to an exercise program." And then there's what is the program itself? You know, I'm very interested in this happening across the entire country. And so I've been working with the leadership of the Commission on Cancer on the question of, well, how would you do this in community oncology? You know, it's not enough to do it in academic medicine, but how do you do this in community oncology? And you can't expect that every community hospital is going to build a gym for their cancer patients. That is just not reasonable to do. So, we start to try to figure out some phone counseling. Could we give people Fitbits and follow them? Could we use technology to help us? Are there telehealth opportunities for us to do? Are there apps that have been built? In fact, there is a [free] app called Cancer Exercise that's on, you know, all of the platforms and available to patients. So there are programs. I've developed a directory of over 2,000 programs that exist across the country for exercise oncology that patients can find, medical oncologists can find.  So there are a lot of people trying to figure out how best to get the information to medical oncologists and other medical professionals so that they can have an 'easy button' to be able to connect their patients to existing programming so that you don't feel like you have to build a whole new program. Dr. Pedro Barata: If I don't have the resources around me, what would be your advice for the care team or for the providers that might not have that available at their site? Where do they start? Who do they reach out to? Who should they be looking at to get more information on how to set it up? Dr. Kathryn Schmitz: I lead an international consortium called Moving Through Cancer. You can find us at movingthroughcancer.org. That's where you'll find the map of all of the programs across the country and the directory. We actually have a triage tool that sits at the front of the directory that allows people to discern what type of exercise they're safe to do. We do recognize that, you know, the 80-year-old that fell last week doesn't need the same program as the 35-year-old that was playing pickleball the day before diagnosis. So, you know, there are different kinds of programs for people at different levels of acuity. We're happy to be helpful to folks to help them set up programs.  But the number one thing is to really be very aware of the power of saying something about doing exercise, just simply the power of saying, "I want you to be moving." Because frankly, I don't think anybody listening to this would disagree, no one benefits from sitting on the couch all day, no one. No one, no one. It doesn't matter how acute their medical issues are. We get people out of bed. We try to move people even when they're in the hospital. So I think saying something is huge. And then, if you can, applying a triage tool, if you can get something embedded within your clinical flow so that you can understand who it is that needs to go to physical therapy as opposed to who's ready for an exercise program. Those are the two things. So triage and referral is kind of step one. And if you can get that done, the rest will fall into place. Dr. Pedro Barata: This is really powerful message, where one, awareness of the care teams. Number two, bring it up to the patient. And then working on the referral, triage and referral process. That's fantastic. Another aspect that comes up quite a bit is like, "Look, this is great, but we have a system that relies on payers to make things happen, or at least to get them approved." And that can be very different or heterogeneous. The coverage can be different. Sometimes already going through a system programs for interventions, therapeutic interventions, let alone probably the insurance is not going to cover that. Is that true? Is it not true? How do you walk through the different insurance supports, perhaps, depending on where you're practicing? Dr. Kathryn Schmitz: You've just hit on the hot button. I've been working on this issue for about nine years now, trying to figure out using efforts to talk to CMS and see if we can get third party payer coverage going. We were making good progress there, and there was a change of administration and a new focus on "Make America Healthy Again," the MAHA movement. And, you know, CMS is really no longer interested in one-off national coverage determination. They instead, they want to know, "How do we make exercise happen for every American over 65?" And my question is, "Well, wait a minute, cancer patients are not just older patients. There's a lot going on there. They need something special." So I've been working on that. It's been working with accrediting bodies for policy with a little p. Very proud of the work that I've done in collaboration with the National Accreditation Program for Breast Centers, trying to get standards to get exercise referrals for breast patients. And I'm currently holding my breath to see whether the CoC is going to try to make some forward motion in this area as well, crossing all period appendages, waiting for news there. So it's not paid for unless it's done by a physical therapist. And, you know, there's published evidence and I have plenty of evidence from UPMC as well, that people don't really want to go to the physical therapist for this. I'm not saying physical therapists aren't great. Physical therapists are great, and there are people who really need to go to physical therapy, and we try hard to get those patients connected. But for the patients that are ready for something more than physical therapy, we really have an uphill battle to try to figure out what insurers are willing to pay for and what the return on investment is.  One of the challenges with the return on investment is that the timeline, time course for return on investment for American insurers is about one year. And I'll remind you that the time course for return on investment for CHALLENGE was 7.9 years. So we have a mismatch there. So we're trying to figure out if we can produce the evidence to show that there is an improvement in unplanned health care utilization. We have documented that for breast cancer. We're working on it for other cancers. If we can document that it is worthwhile to the insurer to pay for these programs, then I believe that they will pay for them. You know, my conversations are very positive with UPMC, which is a very large insurer and a large health plan. We're slowly working our way towards the middle, where there's a program that they can pay for and a program that is efficacious. That's the puzzle we're trying to solve for right now. Dr. Pedro Barata: This has been wonderful and super helpful. Before we wrap it up, is there anything else you would like to share with our listeners? Dr. Kathryn Schmitz: I want to make sure that your audience is aware that there are a variety of ways that exercise oncology is practiced. The program that most oncologists will be familiar with is LIVESTRONG, which is a program at the YMCA. It's a free program. At one point, there were over 800 locations across the U.S. They have contracted since COVID, probably because of COVID. So they still do exist but imagine, if you will, telling your patients that chemo is only available Tuesdays and Thursdays at 7:00 p.m. It would be difficult for patients to get there and get the chemotherapy. The same thing is true for the LIVESTRONG program. It's a fantastic, fantastic program for people who are able to get there, but that's one option. Another option for patients is there are a variety of online opportunities. I'll call out 2Unstoppable for women's cancers. It's literally the number 2Unstoppable.org. It's a free program available to women with cancer to have live, small group training programs. And they're based in Virginia, but they have programs all over the country. And then finally, I just want to overemphasize the app, the Cancer Exercise app. It's literally called Cancer Exercise in the app store. And that is a super duper easy button, very comprehensive, developed by a nurse scientist, Anna Schwartz. And then there are a variety of books. I wrote a book called Moving Through Cancer. There's a new book out [MyExerciseMedicine for Cancer] by Dr. Rob Newton as well, who's an Australian author. And there are certifications for exercise professionals that folks can look into as well through the American College of Sports Medicine. Dr. Pedro Barata: Dr. Schmitz, this is fantastic. Thank you for sharing those great insights with us. Super, super helpful. Thank you for taking the time. Dr. Kathryn Schmitz: Thank you so much. Dr. Pedro Barata: Thank you to our listeners for your time today. Remember, you'll find links to Dr. Schmitz's fantastic Educational Book as well as the JCO articles in the transcript of this episode. I'll invite all of you to go and read. And we'll also include a link to Dr. Schmitz's book titled Moving Through Cancer: An Exercise and Strength Program for the Fight of Your Life, which empowers patients and caregivers in simple five steps.  So with that, please join us again next month on By the Book for more insights on key advances and innovations that are shaping modern oncology. Thank you very much for your attention. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:           Dr. Pedro Barata    @PBarataMD     Dr. Kathryn Schmitz @fitaftercancer Follow ASCO on social media:           @ASCO on X (formerly Twitter)           ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Pedro Barata:    Stock and Other Ownership Interests: Luminate Medical    Honoraria: UroToday    Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon    Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas    Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck     Dr. Kathryn Schmitz: Patents, Royalties, Other Intellectual Property: Fees from the educational program developed by Dr. Schmitz that is now offered through Klose Training and Consulting.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and trends shaping the industry landscape, offering insight into the dynamic interplay between scientific innovation, regulatory challenges, and strategic growth.Starting with the recent departure of Vinay Prasad from the U.S. Food and Drug Administration, particularly from his role as director of the Center for Biologics Evaluation and Research (CBER). Prasad's tenure, though brief, left an indelible mark characterized by controversy and debate over regulatory decisions. His leadership coincided with significant advancements in biologics and gene editing technologies, like CRISPR, highlighting the complexities in balancing innovation with safety standards. Under Prasad's guidance, the FDA faced challenges in navigating these rapid advancements while maintaining rigorous oversight to ensure that new therapies are both effective and safe for public use. Prasad's resignation signals potential shifts in regulatory philosophy at CBER. The biotech industry is watching closely to see how new leadership will influence ongoing and future evaluations of biologics. The change presents an opportunity to reassess how regulatory bodies can better adapt to scientific advancements while ensuring that patient safety remains paramount. The issues faced during Prasad's tenure underscore the need for transparent decision-making and open communication with stakeholders, which are vital for maintaining trust in regulatory processes.Meanwhile, Pfizer has made a strategic entry into the Chinese obesity market with the approval of a GLP-1 drug developed alongside Sciwind Biosciences. This approval represents not only a significant step for Pfizer but also underscores a broader global focus on obesity management. The efficacy of GLP-1 receptor agonists in weight regulation has opened up new market opportunities, highlighting the growing importance of metabolic health solutions in addressing public health challenges.In other news, Johnson & Johnson's Tecvayli-Darzalex combination therapy has received its third national priority recognition from the FDA for treating multiple myeloma. This recognition reflects promising Phase 3 trial results and underscores the critical role of innovative combination therapies in improving outcomes for complex hematologic malignancies. The success of such therapies illustrates how targeted approaches can significantly enhance treatment efficacy and patient quality of life.Strategic acquisitions continue to reshape industry dynamics. Servier's $2.5 billion acquisition of Day One Biopharmaceuticals aims to strengthen its rare cancer portfolio, including a promising glioma drug, Ojemda. This move highlights Servier's commitment to addressing unmet needs in pediatric oncology and rare diseases, emphasizing a broader industry trend towards focusing on niche therapeutic areas with high potential impact.Regulatory activities are gaining momentum as well, with the FDA set to end a nine-month hiatus in advisory committee meetings by reviewing AstraZeneca's oral selective estrogen receptor degrader Truqa. As AstraZeneca seeks to enhance its oncology pipeline, this review signals ongoing innovation in hormone-based cancer therapies and reflects a renewed emphasis on bringing novel treatments to market efficiently.Additionally, Glenmark Pharmaceuticals has achieved a significant milestone with FDA approval for its generic version of GSK's asthma inhaler Flovent. This development exemplifies efforts to improve access to respiratory treatments by providing cost-effective alternatives to branded medications, potentially reducing healthcare costs while enhancing patient access.On an international scale, Taiwan has announced a substantial investment plan aimed at bolstering its drugSupport the show

Watch every episode ad-free & uncensored on Patreon: https://patreon.com/dannyjones Mario Beauregard, PhD, is a cognitive neuroscientist who studies the neuroscience of consciousness and mystical experience, including a study investigating the brain activity of Carmelite nuns. He is co-author of the book 'The Spiritual Brain: A Neuroscientist's Case for the Existence of the Soul'. SPONSORS http://amentara.com/go/dj - Use code DJ22 for 22% off. https://rag-bone.com - Use code DANNY & get 20% off sitewide. https://capl.onelink.me/vFut/zralgyl0 - Download CashApp today! https://chubbiesshorts.com/danny - Use code DANNY for 20% off. https://whiterabbitenergy.com/?ref=DJP - Use code DJP for 20% off EPISODE LINKS The Spiritual Brain - https://a.co/d/0cZDv6gn https://www.drmariobeauregard.com FOLLOW DANNY JONES https://www.instagram.com/dannyjones https://twitter.com/jonesdanny OUTLINE 00:00 - Dr. Beureguard's childhood mystical experience 03:52 - Discovering everything is connected as one 07:08 - Mario "downloaded" his life's mission 09:54 - Mario's failed journey to become a priest 15:44 - Mario's second mystical experience 21:08 - What Mario saw in Heaven 23:30 - Mario's biological markers say he's 20 years younger 29:19 - How Mario became a neuroscientist 30:07 - The roots of modern science 31:02 - When science lost its spiritual connection 34:27 - Testing memory molecules for Pfizer 36:00 - Pfizer pushed ineffective Alzheimer's drug in 1994 41:12 - Why Mario fled Canada during the pandemic 43:00 - Justin Trudeau paid off court judges during the pandemic 46:31 - The Catholic Church tried to bribe Mario 53:38 - Why the church is pushing new science 01:01:10 - Carmelite nuns study 01:07:00 - 1% of seizures trigger mystical experiences 01:09:57 - Johns Hopkins psychedelics + religion study 01:13:07 - Mario tested all drugs before experimenting 01:14:44 - Human psyche vs. consciousness 01:16:55 - "Consciousness" is the scientific God 01:21:56 - Non-physical information 01:25:17 - Where thoughts come from 01:30:14 - Holotropic breathwork to expand consciousness 01:34:58 - New consciousness research 01:38:02 - Who's funding consciousness research 01:40:11 - Studies on people who survived death 01:44:58 - Holosynthesis 01:49:33 - What happens when you "overdose" psychedelics 01:52:20 - Church-sanctioned psychedelic use 01:55:57 - Humans are behaving like robots 02:02:54 - Joan Jett's spiritual transformation 02:05:37 - NDEs vs. life reviews 02:07:21 - Memories of past lives 02:15:35 - How to expand consciousness using sound 02:21:30 - Bufo: DMT times 1,000 02:24:39 - Mapping neurological effects across religions 02:26:25 - The Dalai Lama's lesson on attention 02:32:04 - What the brains of uncontacted tribes might look like 02:37:55 - Explanation of the universe Learn more about your ad choices. Visit podcastchoices.com/adchoices

"The disease is increasingly managed as a chronic condition rather than a diagnosis with an immediate terminal outcome. Particularly, with earlier and more effective and sustained treatment options, we can make this disease a very chronic, long-term, livable condition. I want to make sure that patients are aware that this is not a death sentence. This is something that patients can live with for the long term," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about long-term multiple myeloma considerations for oncology nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 6, 2027. Ann McNeill is on the speakers' bureau for Pfizer. This financial relationship has been mitigated. All other planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to management of long-term side effects related to multiple myeloma and treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 401: Multiple Myeloma Treatment Considerations for Oncology Nurses Episode 398: An Overview of Multiple Myeloma for Oncology Nurses Episode 339: A Lesson on Labs: How to Monitor and Educate Patients With Cancer Episode 201: Which Survivorship Care Model Is Right for Your Patient? ONS Voice articles: Effective Care Transitions Are Essential for New Multiple Myeloma Treatments Infection Prevention for Oncology Nurses Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations Nurse-Led Survivorship Programs Sexual Considerations for Patients With Cancer Oncology Nursing Forum articles:  A Qualitative Study of the Experiences of Living With Multiple Myeloma Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study ONS book: Multiple Myeloma: A Textbook for Nurses (third edition) ONS Huddle Cards: Pain Management Sexuality Survivorship Care Plan ONS Learning Libraries: Hematology, Cellular Therapy, and Stem Cell Transplantation Survivorship ONS Symptom Intervention resources: Chronic Pain Fatigue Peripheral Neuropathy American Cancer Society: Living as a Multiple Myeloma Survivor Blood Cancer United: Resources for Healthcare Professionals International Myeloma Foundation: Resources and Support for the Myeloma Community Multiple Myeloma Research Foundation: Empower Patients and the Community To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We do consider myeloma an incurable hematologic malignancy, even though we have had improvements in survival. But just like for any malignancy, our goal is to maximize survival. We want to eliminate as many myeloma cells as we possibly can. And subsequently, we want to improve the quality of life for these patients in the long term. So those are basically our treatment goals. That's what we think of when we're treating patients all throughout their treatment journey." TS 1:39 "It is very typical for patients along their journey to have received several lines of therapy. I think it's important to realize that the cells acquire new mutations, making them more resistant to these further subsequent lines of therapy. We see quicker, more aggressive relapses in those patients with multiple prior lines of therapy. We can see an increase in the CRAB symptoms, which are the calcium elevations, the renal dysfunction, profound anemia, and even bone disease. We can see a rapid rise in the monoclonal protein in the labs or even a very rapid rise in the involved light chain in that serum free light chain assay, so it's important to monitor these labs." TS 9:14 "All oncology nurses are focusing on these survivorship plans now. And I think that's a great thing when you think about a diagnosis of cancer and a survivorship plan, because it means these patients are living a longer time. We still look at long-term health maintenance guidelines depending on the patient's sex and their age. ... I think preventing infection is always going to be something absolutely on the forefront in our survivorship plan with myeloma. I mean, myeloma is an immune system malignancy. The treatments that we have given patients can sometimes, especially in later life therapies, further compromise the immune system. So, we're always looking to prevent serious infection." TS 12:46 "Patients get treatment, especially induction therapy. They may or may not get transplant. They may have been on a very minor maintenance schedule, depending on their age. And they feel really well. And then they decide not to return for their follow-up because they feel so good. I think nurses are critical in the communication aspect of the patient-provider aspect. So, nurses are really the key means of communication. The providers are absolutely important—the physicians, the nurse practitioners and every other member of the team—but I think the nurses have a really special rapport with patients. They're usually the ones providing the education on the treatment regimens. They're managing the toxicity profiles. They're doing all the coordination of care between visits. They are really going to be the ones telling the patient, 'Hey, you're going to feel good and that's a wonderful thing, but you still need to come once a month or once every six weeks or once every two months for your labs.'" TS 15:17  "It has been amazing. The science, the research, the treatments, the approvals from the U.S. Food and Drug Administration. Survivorship has improved dramatically. Let's take the first few years of the new century, right? The five-year survival rate was about 38%. If you then jump to 2015–2019, which is still seven plus years ago, it has doubled. So, we're talking about anywhere from 60%–80% over a five-year survival. So that's an amazing improvement in their five-year survival rate for myeloma." TS 23:28 "Survivorship in myeloma begins at diagnosis, not just after treatment. And I think that because it is managed as a chronic, often relapsing disease, it does require lifelong evolving care. Patients should realize that they will know us for the rest of their lives. We will know everything about you. I always tell them, 'I will know everything about your hobbies, your children, your grandchildren, what you love to do on the weekends.' It's very important that that point is made right at diagnosis, not just after so many lines of treatment. It's very important that we are going to follow these patients throughout their journey." TS 28:18

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of developments that highlight the dynamism and complexity of our industry. The pharmaceutical and biotech sectors continue to evolve rapidly, driven by scientific innovations, regulatory shifts, and strategic initiatives.Eli Lilly's recent move to launch "Employer Connect," a platform aimed at improving access to its obesity medications, marks a significant step in addressing the growing public health issue of obesity. This initiative reflects the increasing influence of employer-driven healthcare solutions in managing chronic conditions. By directly involving employers, Eli Lilly seeks to enhance both the accessibility and affordability of its treatments, which could lead to better patient outcomes and reduced healthcare costs associated with obesity-related complications.In dermatology, Galderma has doubled its sales projections for Nemluvio (nemolizumab), an atopic dermatitis treatment, following a successful market debut. The revised projection to over $4 billion in peak annual sales underscores Nemluvio's strong market performance against competitors like Dupixent. This success not only highlights the drug's therapeutic efficacy but also indicates robust market demand for innovative dermatological therapies.Regulatory landscapes remain pivotal in shaping the industry. Vanda Pharmaceuticals' ongoing efforts to expand Hetlioz's label for jet lag treatment have been met with regulatory challenges since 2019. The FDA's response to Vanda's request for a public hearing underscores the complexities involved in navigating approval processes for label expansions. The outcome of such hearings could have broader implications for similar drugs seeking label amendments.Geopolitical dynamics also influence biopharma investments, with Ireland emerging as a stable manufacturing hub amidst global uncertainties. Despite geopolitical tensions, U.S. investments continue to flow into Ireland, highlighting its strategic importance as a location for biopharmaceutical manufacturing and innovation.In oncology, Pfizer is advancing its research and development strategy under Jeff Legos' leadership by leveraging its $43 billion acquisition of Seagen. The aim is to build an antibody-drug conjugate empire while advancing a PD-1xVEGF bispecific drug licensed from 3SBio. This approach underscores Pfizer's commitment to expanding its oncology pipeline through innovative therapies and combination regimens that could potentially transform cancer treatment paradigms.Meanwhile, Merck KGaA faces challenges with declining U.S. sales of Mavenclad due to anticipated generic competition. This situation reflects a broader industry trend where pharmaceutical companies must navigate patent expirations and generic market entries that threaten revenue streams of established products.Leo Pharma's launch of a direct-to-consumer campaign for Anzupgo, targeting hand eczema treatment, signifies the growing role of consumer engagement in pharmaceutical marketing strategies. Such approaches are becoming increasingly important in reaching patients directly.Collaborations remain a key driver of innovation within the industry. Daiichi Sankyo's partnership with German medtech Gaia to commercialize Lipodia—a digital therapeutic for high cholesterol management—illustrates the convergence between digital health technologies and traditional pharmaceuticals.In gene therapy news, uniQure finds itself in a contentious dialogue with the FDA over its Huntington's disease therapy. The debate centers around uniQure's claim that the FDA requested a "sham trial," which the agency denies. This situation underscores regulatory complexities surrounding gene therapies targeting rare diseases.Simultaneously, PepGen faces a partial clinical hold on its muscle wasSupport the show

Dr. Aly-Khan Lalani and Dr. Christopher Wallis also highlight Canadian-led innovation in the GUNS trial and early data from the PAnTHA study, and discuss how Prostate Cancer Working Group 4 may redefine trial design. Episode 35 is the first of three ASCO GU recap episodes, so don't miss Episode 36 on bladder cancer and Episode 37 on kidney cancer!The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.

Dr. Aly-Khan Lalani and Dr. Christopher Wallis discuss practice-changing data in non-muscle invasive and muscle-invasive bladder cancer, including perioperative strategies,bladder-sparing approaches, and emerging targeted therapies. Don't forget to watch or listen to Episode 35 and Episode 37 for updates on prostate and kidney cancer!The View on GU with Lalani & Wallis integrates key clinicaldata from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.

Dr. Aly-Khan Lalani and Dr. Christopher Wallis also discuss the RAMPART trial, LITESPARK-011, and the K-COMPASS model. This final recap episode highlights how evolving adjuvant strategies and combination sequencing are reshaping the kidney cancer landscape. Be sure to listen to Episodes 35 and 36 for the full ASCO GU recap, covering key updates in prostate and bladder cancer!The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.

We've had many conversations on Raise the Line about the challenges of health communication in today's world of information overload, but none of our guests have the kind of expertise Dr. Tesfa Alexander has acquired in a career that has taken him from Madison Avenue to the halls of government and academia. From guiding tobacco education research at the FDA to leading public health initiatives at MITRE, Dr. Alexander has developed a deep understanding of the science and strategy behind effective health communication. “Successful campaigns keep the long game in mind where you want to develop a lasting relationship with your target audience,” he tells host Lindsey Smith. That relationship needs to be built on understanding culture, beliefs, priorities and daily realities, and only then can you develop messaging that will resonate, he explains. Dr. Alexander also believes these relationships can be leveraged to help people sort out facts from misleading or inaccurate claims. “I strongly recommend shifting our focus from combating misinformation head on, and instead working with the communities who we are seeking to serve.” This fascinating look at communication science also covers: How stories drive belief; The importance of working with community partners who are trusted messengers;  The power of audience segmentation. Tune in as Dr. Alexander unpacks what it takes to influence beliefs, and ultimately behaviors, in an era defined by misinformation and institutional mistrust. Mentioned in this episode:Lerner Center for Public Health Advocacy If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Host: Sabiha Gati Guest: Thomas F. Luescher Want to watch that extended interview on The future of guidelines in an era of Big Data and AI, go to: https://esc365.escardio.org/event/2556?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2556 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.  The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and Thomas F. Luescher have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology this Week: A concise summary of recent studies The future of guidelines in an era of big data and AI Exercise in hypertrophic cardiomyopathy Snapshots Host: Sabiha Gati Guests: Kostas Koskinas, Thomas F. Luescher, Michael Papadakis, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/2556 Want to watch the extended interview on The future of guidelines in an era of Big Data and AI, go to: https://esc365.escardio.org/event/2556?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.  The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and Thomas F. Luescher have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Shawn Lipe is an art gallery and action house owner.  In this episode, he talks about how his collegiate exposure with Japanese culture changed his life, recognizing the moments to show up, knowing the kind of business you are in, the value in stories about your stuff, and the obligation of pivots.About the GuestOwner and gallery director at Woodard Lipe Fine Art and Auction, Shawn Lipe provides advisory strategies for private St. Louis art collections, gallery support, and facilitate institutional sales. Woodard Lipe auctions and Gallery provide a unique sales platform for art and fine collections, providing the highest level of representation. He appraises artwork for collection divestment or acquisition and work closely with a multidisciplinary staff to research and provide valuations of fine art, special collections, estate jewelry, vintage couture, classic automobiles, historic weaponry, fine Judaica, American folk, and American and European contemporary art, and sports memorabilia.In support of this mission, Woodard Lipe Fine Art and Auction provides CAGA certified appraisals for insurance loss recovery, fiduciary and trust equitable assets distribution, or probate and estate tax documentation. As a practicing artist and glass artist for the past 38 years, Shawn taught glassblowing as an adjunct professor in the Department of Art and Art History at the University of Miami, Coral Gables campus and maintained a private studio in Fort Lauderdale participating in both group and solo exhibitions. Additionally, he has conducted art research and curation at Wolfsonian Museum, Florida International University, and Krannert Art Museum at University of Illinois, Champaign-Urbana. Shawn received his Masters in Environmental Chemistry from SIU Edwardsville.. Professionally, he conducted research, chemical analysis, and drafted international regulatory documentation for Mallinckrodt Pharmaceuticals and was a past contributing senior regulatory affairs consultant for Cardinal Healthcare and Pfizer.To learn more, visit:linkedin.com/in/jason-Shupp-18b4619bListen to more episodes on Mission Matters:https://missionmatters.com/author/Jason-Shupp/

What if the greatest turnaround in modern corporate history wasn't driven by financial engineering or restructuring, but by an unshakeable belief in science and human talent? In this powerful episode of the Positive Leadership Podcast, I welcome Pascal Soriot, CEO of AstraZeneca—a visionary leader who transformed a struggling pharmaceutical company into a defining global force in oncology, cardiovascular disease, and respiratory care. He is also someone I know personally: I had the privilege of serving on the AstraZeneca board between 2008 and 2016, and I was in the boardroom when we appointed him as CEO. What makes Pascal's leadership so rare is his non-traditional ascent. He didn't start with an elite corporate playbook; his foundational lessons were grounded in learning the value of loyalty and protecting his people. By beginning his professional life as a practicing veterinarian, he developed a profound sense of empathy—traits that continue to drive his unwavering commitment to putting patients first today. But Pascal's story isn't your typical corporate trajectory. Raised in a humble background where he learned early lessons about loyalty, standing up for his team, and defending his territory, he began his professional life not in business, but as a veterinarian. It was this experience that profoundly shaped his empathy and his "patient-first" approach to leadership. In our conversation, we explore: 

It's been over two decades now since viagra was first approved for use in 1998, the little blue pill from Pfizer becoming the first oral treatment for erectile dysfunction. Its use has steadily increased over the years, with the NHS reporting just under 3 million prescriptions in 2016, compared to 1 million in 2006. Its success has led pharmaceutical companies to look for a female equivalent. In 2015, the American Food & Drug Authority approved a pink pill called Flibanserin, marketed as Addyi, which became known as female viagra. How does it work? Let's cut to the chase then; does female viagra really work? What can be done to help women who want to boost their libido? ⁠In under 3 minutes, we answer your questions!⁠ To listen to the last episodes, you can click here: ⁠⁠What is demisexuality?⁠⁠ ⁠⁠What is sologamy?⁠⁠ ⁠⁠What is intersectionality?⁠⁠ A podcast written and realised by Joseph Chance. First broadcast : 18/02/2022 Learn more about your ad choices. Visit megaphone.fm/adchoices

Brought to you by the Founders Unfiltered podcast by A Junior VC - Unscripted conversations with Indian founders about their story and the process of building a company. Hosted by Aviral and Mazin.Join us as we talk to Mazin about his journey and the experiences that shaped his path.He shared how A Junior VC evolved from a simple newsletter into a thriving community and eventually a fund, along with the lessons he learned along the way.We also dived into his journey of hosting the AJVC Unfiltered podcast alongside Aviral, and the conversations and insights that came from it.Mazin completed his BSE and MSE from University of Michigan and later pursued his MBA from INSEAD.Over the years, he worked across global organizations including Deloitte, Emirates NBD, and Pfizer.He is currently a Senior Product Manager at Agoda.

This week, we explore early colorectal cancer. Maybe it's just this week, but there were plenty of “IDEAS” around. Michael highlights the importance of choosing an appropriate adjuvant regimen, whether that be FOLFOX or CAPOX. Josh digs a bit deeper and, as the name suggests, looks at whether patients with liver metastases can be cured with chemotherapy and a liver transplant.Studies discussed in this episode:IDEASTransMETEORTCFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

In this episode, we review advancements in migraine care and the standardization that can help physicians and other practitioners take the pain out of managing this condition, treating and preventing symptoms. https://drive.google.com/file/d/1YqEz5Ih_lmOnAk7nJsddfu8uXb3dYVjr/view?usp=sharing Supported by Pfizer

Support your health journey with our private practice! Explore comprehensive lab testing, functional assessments, and expert guidance for your wellness journey. Find exclusive offers for podcast listeners at nutritionwithjudy.com/podcast. _____Michael and I dive into how childhood trauma reshapes the nervous system, drives addiction, and contributes to chronic illness, mental health struggles, and even premature death. We break down the CDC's ACE (Adverse Childhood Experiences) score, including the powerful data showing that an ACE score is associated with losing years of life, and discuss why trauma may be the hidden driver behind inflammation, immune dysfunction, and chronic disease. Make sure to listen to the full interview to learn more.Michael Menard is an inventor, entrepreneur, and author who grew up as the second oldest of 14 children in Kankakee, Illinois, later discovering that he and his siblings experienced complex childhood trauma. As Vice President of Engineering at Johnson & Johnson, his 14 patents transformed global manufacturing, and his expertise has been sought by the United Nations, NASA, Coca-Cola, and Pfizer. He is the founder of United Against Childhood Trauma (UACT) and the bestselling author of multiple books, including The Kite That Couldn't Fly and Greater Than Gravity.We discuss the following: Who is Michael MenardTrauma's hidden death tollACEs defined by the CDCACE score shortens lifespanCortisol damages brain and bodyShame prevents trauma healingBuilding ACE 2.0 intensityWholeness and EMDR healingThe sacred first 60 daysThe Paradox of Childhood Trauma_____EPISODE RESOURCESUnited Against Childhood Trauma (UACT)WebsiteInstagramThe Kite That Couldn't Fly (Memoir)_____WEEKLY NEWSLETTER 

Why you should listenDoug Pelletier has spent 35 years winning enterprise accounts (Disney, Pfizer, Xerox) as a small Salesforce partner, proving that company size is irrelevant when your positioning and sales approach are right.Learn why Doug hired a General Manager at just six employees, and how that single WHO decision helped him scale to 130 people without burning out on tasks outside his strengths.Get Doug's approach to managing cash flow daily (a discipline he's maintained for 17 years) and why he says cash flow matters more than profitability for consulting firm owners.About Doug PelletierDoug Pelletier is the Founder and CEO of Trifecta Technologies, a technology consulting firm he launched in 1991 that has grown into a trusted Salesforce and enterprise solutions partner for leading organizations. A sales- and strategy-led founder, Doug focuses on identifying real business problems, building executive relationships, and hiring strong operational leadership early – allowing him to concentrate on growth, client strategy, and selling. His leadership is shaped by decades of experience and a strong emphasis on financial discipline and long-term stability. Having gone through multiple industry shifts, Doug views AI as a major inflection point and leads Trifecta in helping organizations move beyond the hype to apply data, architecture and AI in practical ways that drive meaningful business outcomes. Resources and LinksTrifecta.comDoug's LinkedIn profileSnowflakeDatabricksApolloZoominfoPrevious episode: 667 - The Land-and-Expand PlayCheck out more episodes of the Paul Higgins PodcastSubscribe to our YouTube channel: @PaulHigginsMentoringJoin our newsletterSuggested resources

We're marking Rare Disease Month 2026 by highlighting the powerful story of Shanthi Hegde, a young patient advocate working to transform how bleeding disorders are understood, treated, and supported. This work is fueled by her own arduous journey with two rare bleeding disorders and immune dysregulatory syndrome, and an extended diagnostic odyssey marked by dismissal, underdiagnosis, and structural bias. “I was told many times by many providers that these disorders are not common in Indians and that my bruises were there just because I'm brown.” Admirably, Shanthi pushed past this mistreatment, advocated for her medical needs, and devoted herself to tackling a range of issues confronting rare disease patients from mental health access to affordable drug pricing to research equity. In this remarkable Year of the Zebra conversation with host Lindsey Smith, you'll also learn about: Shanti's work with the Hemophilia Federation of America; How gaps extend beyond treatment to include insurance coverage, provider training, and substance use care; What clinicians can do to improve the work they do with rare disease patients. Join us for a conversation that connects patient voice to system change, and explores what real equity for rare disease communities will require. Mentioned in this episode:Hemophilia Federation of AmericaShanthi's LinkedIn Profile If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Measuring AI marketing ROI has become one of the most uncomfortable conversations in tech and marketing teams. Everyone knows AI is "important." Fewer teams can explain what success actually looks like. Even fewer can tie adoption to real outcomes rather than experimentation for its own sake. For developers and technical leaders, this isn't a tooling problem — it's a decision-making problem. The teams that win are the ones that slow down just enough to define value before they ship. About Meeky Hwang Meeky Hwang's journey resonates with entrepreneurs, technical leaders, and anyone navigating the intersection of technology and business. As CEO and Co-Founder of Ndevr, a digital solutions development agency, Meeky brings over 20 years of experience building resilient, scalable platforms for organizations including Johnson & Johnson, Pfizer, Forbes, PMC, and Bloomberg. Her work goes beyond website development—she focuses on long-term digital solutions that improve performance, streamline workflows, and align technology with business strategy. Equally important is Meeky's perspective as a woman leading in a male-dominated industry. She has navigated the challenges of technical leadership, entrepreneurship, and scaling a services business while building credibility and strong teams along the way. Her experience offers an honest look at what it takes to grow as a leader without losing sight of innovation, people, or purpose. Follow on LinkedIn and her Website. Measuring AI marketing ROI when the hype is louder than the data AI adoption today often starts with pressure instead of purpose. Tools arrive before goals. Budgets get approved before success criteria exist. That's the first red flag. If you can't articulate what improvement AI is supposed to create — conversion lift, content velocity, operational savings, personalization accuracy — you're not measuring ROI. You're chasing momentum. Measuring AI marketing ROI by defining outcomes before tools The most effective teams reverse the typical process. They define outcomes first, then ask which capabilities might support those outcomes. That discipline alone filters out most bad investments. Before selecting tools, answer three questions: What problem are we solving? How will we measure improvement? What happens if this fails? If those answers feel vague, that's your signal to pause. Measuring AI marketing ROI with clear baselines and success metrics ROI requires comparison. Without a baseline, every result looks impressive — or disappointing — depending on expectations. Establish: A pre-AI performance baseline A specific success threshold A review window short enough to stop bad bets early This turns AI from a belief system into an experiment with guardrails. Measuring AI marketing ROI without wasting budget on "maybe" features Not every feature deserves implementation just because it exists. Time and money are always the real constraints. Teams that succeed evaluate AI features the same way they evaluate architecture decisions: cost, risk, effort, and impact. When those tradeoffs are visible, priorities clarify quickly. Measuring AI marketing ROI while Google, SEO, and platforms keep shifting AI doesn't exist in isolation. SEO changes, platform updates, and algorithm shifts constantly reshape the playing field. That makes flexibility more valuable than novelty. Incremental improvements that survive change often outperform bold implementations that lock teams into fragile solutions. Measuring AI marketing ROI alongside compliance requirements and regional rules Global websites introduce real constraints — privacy, consent, accessibility, and regulatory differences. AI features that ignore compliance increase risk faster than they increase value. Measuring AI marketing ROI with a repeatable compliance checklist A checklist-driven approach ensures new features don't break trust or regulation: Regional consent and privacy rules Accessibility requirements Data handling expectations This protects ROI by preventing costly rework. Measuring AI marketing ROI through discovery, QA, UAT, and launch checklists Strong discovery reduces downstream chaos. Structured QA and UAT validate assumptions. Launch checklists prevent avoidable mistakes. AI doesn't replace these fundamentals — it amplifies their importance. Measuring AI marketing ROI as a founder: delegate, stay lean, and still scale Technical founders often delay hiring because they can do the work themselves. That works — until it doesn't. Sustainable ROI requires delegation. Growth depends on trusting others to execute while leaders focus on direction, not tickets. Callout: AI ROI Scorecard Define outcomes, baselines, and review windows before implementation Decide early whether to pilot, pause, or proceed Callout: Website Launch Checklist (Minimum Viable) QA, UAT, accessibility, and responsiveness checks Hosting, CDN, and integration validation Callout: Delegation Rules for Technical Founders Decide what you keep vs. hand off Train once, so execution scales later Conclusion Measuring AI marketing ROI isn't about skepticism — it's about clarity. When teams define value first, use disciplined checklists, and resist hype-driven decisions, AI becomes a multiplier instead of a distraction. If you want better outcomes, start with better questions — and build from there. Stay Connected: Join the Developreneur Community We invite you to join our community and share your coding journey with us. Whether you're a seasoned developer or just starting, there's always room to learn and grow together. Contact us at info@develpreneur.com with your questions, feedback, or suggestions for future episodes. Together, let's continue exploring the exciting world of software development. Additional Resources Online Communities and Marketing Creating your Marketing Site Branding and Marketing Fundamentals with Kevin Adelsberger Develpreneur - Forward Momentum Podcast Videos – With Bonus Content

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of transformative events shaping the industry, from regulatory approvals and licensing deals to clinical trial outcomes and strategic partnerships, each carrying profound implications for drug development and patient care.Starting with the biopharma landscape in China, there's a notable shift in the valuation of licensing deals, which have seen a significant increase of 230% in upfront payments. This surge, from $52 million to $172 million between 2022 and early 2026, signals China's growing influence and competitiveness in the sector. Historically considered a low-cost option for licensing deals, China's enhanced innovation capabilities are now attracting Western companies seeking strategic collaborations. The implications are vast, offering Western firms an opportunity to tap into China's expansive market potential and leverage local expertise, underscoring the country's pivotal role in global drug development.In regulatory news, Pfizer's Braftovi (encorafenib) combination therapy has achieved full FDA approval for colorectal cancer treatment. This is a critical development, expanding therapeutic options for a particularly challenging cancer type. The approval highlights the increasing importance of targeted therapies in oncology, reflecting ongoing efforts to address unmet medical needs by enhancing the treatment arsenal available to clinicians. As cancer remains a major global health issue, such advancements are vital for improving patient outcomes.Novartis is making headlines with its substantial investment strategy to boost radiopharmaceutical production capabilities in the United States. With new manufacturing sites planned in Texas and Florida as part of a broader $23 billion investment, Novartis is positioning itself at the forefront of radiopharmaceuticals—a field offering innovative cancer treatments through targeted radiation delivery. This strategic move not only strengthens Novartis's presence in this burgeoning field but also signifies a broader industry trend towards cutting-edge technologies that promise more precise and effective treatment modalities.Shifting focus to drug pricing dynamics, Novo Nordisk has announced plans to reduce list prices for its GLP-1 medications, Ozempic and Wegovy, starting next year. While self-pay channels remain unaffected, this price reduction reflects broader industry trends towards addressing medication costs amidst mounting pressure from healthcare stakeholders. The move aims to enhance affordability for diabetes and obesity treatments, crucial given the rising prevalence of these conditions globally.In gene therapy, BioMarin has faced challenges with its hemophilia A gene therapy, Roctavian. Despite potential clinical benefits, BioMarin's efforts to divest the therapy have resulted in a $240 million financial setback. This scenario underscores the inherent complexities and financial risks associated with developing advanced therapies like gene therapies. Meanwhile, Pfizer has shown continued interest in gene editing technologies by securing global rights to Beam Therapeutics' liver-targeted gene editing candidate. This decision marks Pfizer's strategic pivot towards promising frontiers in therapeutic innovation.Emerging biotech BreezeBio has rebranded and secured $60 million in funding to advance its research in genetic medicine focused on restoring immune tolerance in type 1 diabetes. This strategic pivot towards addressing autoimmune diseases using innovative genetic approaches highlights ongoing efforts within the biotech sector to tackle complex health challenges through cutting-edge science.Collectively, these developments illustrate dynamic trends within the pharmaceutical and biotech sectors: a shift towards more equitable global partneSupport the show

Guest: Martin Brenner, Ph.D., Chief Executive Officer and Chief Scientific Officer at iBioCompany: iBio, Inc. (NASDAQ:IBIO)Website: https://ibioinc.com/Martin's Bio:Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. Most recently, Dr. Brenner served as the CSO at Pfenex Inc., which, using its patented Pfēnex Expression Technology® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million in October 2020. Previously, Dr. Brenner served as the CSO at Recursion Pharmaceuticals, Inc., a company focused on accelerating drug discovery for rare diseases and diseases with high unmet medical need. Prior to his time at Recursion, he was Vice President and Head of Research & Early Development at Stoke Therapeutics, Inc., a biotechnology company using antisense oligonucleotides to increase gene expression for the treatment of rare diseases. Prior to Stoke, he was Executive Director at Merck, where he built a biotech unit from scratch, focusing his team's research on diabetes and nonalcoholic steatohepatitis (NASH). Earlier in his career, Dr. Brenner was the Senior Director and Head of cardiovascular, renal, and metabolism (CVRM) biosciences at AstraZeneca. In addition, Dr. Brenner was an Associate Research Fellow at Pfizer where he led the islet biology and in vivo pharmacology in the CVMED Target Exploration Unit before assuming the role of Head of the Insulin Resistance Group.Company Description: iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. iBio's mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a compelling array of advancements and strategic shifts that are shaping the healthcare landscape across the globe.In recent times, the pharmaceutical and biotech sectors have showcased remarkable resilience and innovation, driving forward with significant scientific breakthroughs and clinical trial results. A standout achievement comes from Novo Nordisk, whose recent Phase 2 trial results for its triple agonist targeting obesity reported a remarkable weight loss of up to 19.7% in patients over 24 weeks. This promising development positions Novo Nordisk as a formidable contender in the obesity treatment market, potentially affecting giants like Eli Lilly. With obesity being a significant global health challenge, these findings underscore the potential of multi-targeted approaches in managing this complex condition.Regulatory landscapes continue to evolve, with pivotal approvals marking milestones for therapies targeting rare diseases. Immedica Pharma's Loargys received FDA approval for treating hyperargininemia associated with arginase 1 deficiency, highlighting perseverance in overcoming regulatory hurdles after a prior rejection. Additionally, Sanofi and Regeneron's Dupixent achieved its ninth FDA approval, underscoring its versatile potential across multiple indications. These approvals not only reflect regulatory progress but also emphasize the critical role of persistence in drug development.Ethical considerations remain at the forefront of industry discussions, particularly highlighted by Novartis' settlement in a lawsuit concerning the use of Henrietta Lacks' cells without consent. This resolution underscores ongoing ethical challenges within biomedical research, emphasizing the need for ethical vigilance as companies increasingly rely on human-derived materials.Significant business trends are shaping strategic directions within the industry. Pfizer's acquisition of marketing rights for Sciwind's GLP-1 receptor agonist in China exemplifies a calculated move to dominate the obesity treatment market. This strategic acquisition allows Pfizer to leverage China's vast market potential for type 2 diabetes medications and positions it favorably for future weight loss treatments.On the manufacturing front, AbbVie has made substantial investments in U.S. infrastructure, committing $380 million to new North Chicago API plants as part of a decade-long strategy to inject $100 billion into U.S. operations. This initiative highlights a commitment to bolstering domestic production capabilities amidst global supply chain uncertainties.The complexities of drug development are further illustrated by Roche's decision to halt the development of Enspryng for Duchenne muscular dystrophy due to unsatisfactory progress. This shift in focus reflects the inherent challenges of drug repurposing and the necessity of robust clinical evidence to support new indications.Geopolitical factors also play a significant role in shaping industry dynamics, with recent U.S. Supreme Court decisions impacting international trade agreements. Such geopolitical influences can significantly affect pharmaceutical companies' operations and strategic planning.The collaboration between Astellas and Vir Biotechnology reflects another significant trend in strategic partnerships within the industry. Their $1.7 billion deal centered on a novel bispecific T-cell engager for prostate cancer underscores the growing importance of immuno-oncology and innovative approaches to targeting hard-to-treat cancers.The regulatory front continues to see transformative changes with the FDA unveiling draft guidance for a new approval pathway tailored for bespoke gene-editing therapies. This initiative could expedite personalized genetic treatments and transform patSupport the show

At Pfizer, the employer brand is an experiment in progress where hypotheses are constantly tested to improve activation. We learn how they measure their progress as they go and weave employer brand concepts into the recruitment process. Anne Kennedy Dotson is the Global Head of Employer Brand, Recruitment Marketing & University Relations at Pfizer. Anne Kennedy Dotson on LinkedIn: https://www.linkedin.com/in/anne-kennedy-dotson-8362128/ Careers at Pfizer: https://www.pfizer.com/about/careers Subscribe to this podcast: https://employerbrandingpodcast.com Measure your employer brand: https://employerbrandindex.co Thanks for tuning in!

The Developer to CEO transition rarely starts with a bold declaration like, "I'm going to run a company." More often, it begins quietly—by taking on one more responsibility, saying yes to a new opportunity, or stepping into a role that stretches just a little beyond your comfort zone. In this episode of the Building Better Developers podcast, part of our Forward Momentum season, we talk with Meeky Hwang about how that transition unfolds in real life. Her path—from developer to agency founder and CEO—reflects a pattern many experienced engineers recognize only in hindsight. Over time, those small decisions add up. You stop thinking only about code and start thinking about people, clients, sustainability, and direction. At some point, you realize you're no longer just building software—you're building a business. About Meeky Hwang Meeky Hwang's journey resonates with entrepreneurs, technical leaders, and anyone navigating the intersection of technology and business. As CEO and Co-Founder of Ndevr, a digital solutions development agency, Meeky brings over 20 years of experience building resilient, scalable platforms for organizations including Johnson & Johnson, Pfizer, Forbes, PMC, and Bloomberg. Her work goes beyond website development—she focuses on long-term digital solutions that improve performance, streamline workflows, and align technology with business strategy. Equally important is Meeky's perspective as a woman leading in a male-dominated industry. She has navigated the challenges of technical leadership, entrepreneurship, and scaling a services business while building credibility and strong teams along the way. Her experience offers an honest look at what it takes to grow as a leader without losing sight of innovation, people, or purpose. Follow on LinkedIn and her Website. Developer to CEO transition starts with "accidental" opportunities For many engineers, this transition begins almost by accident. A consulting role exposes you to different industries. A startup forces you to wear multiple hats. An agency environment teaches you how delivery, relationships, and trust intersect. None of these roles comes with a "future CEO" label. But they do build instincts—how to prioritize, how to adapt, and how to make tradeoffs when perfect solutions aren't possible. Those instincts matter far more than a perfectly mapped career plan. Developer to CEO transition lessons from consulting, startups, and agencies Each environment contributes something different to the Developer to CEO transition. Consulting sharpens communication and expectation-setting. Startups teach ownership and resilience. Agencies reveal what it takes to scale work without burning people out. Individually, these roles can feel chaotic. Together, they form a foundation that prepares developers for leadership long before they realize that's where they're headed. Developer to CEO transition and the mindset shift to full responsibility There's a moment in the transition when responsibility feels heavier. Decisions don't stop at your team or your sprint—they ripple outward. Hiring, pricing, client relationships, and long-term viability all land on your plate. Problems are no longer theoretical. They're personal. This shift changes how leaders think. It forces clarity, prioritization, and the ability to move forward without perfect information. Developer to CEO transition accelerators: mastermind and founder groups One of the most impactful accelerators in the Developer to CEO transition is joining founder communities earlier than you think you need them. Mastermind ROI for New Owners Real conversations about hiring, benefits, pricing, and mistakes Exposure to how other founders actually run their businesses Founder groups shorten the learning curve by replacing isolation with shared experience. Instead of guessing, you learn from people who've already been there. Developer to CEO transition accountability: learning faster through peers Accountability is often underestimated in the Developer to CEO transition. Founder groups create a rhythm of progress—not through pressure, but through shared momentum. The "Accidental" Path That Works Follow opportunities that increase learning, not just status Optimize early for exposure and experience, not polish When you know you'll report back to peers who care, progress stops being optional. Developer to CEO transition when your role forces personal growth The Developer to CEO transition also reshapes how leaders show up. Many founders start as quiet contributors, comfortable behind the scenes. Leadership changes that. Mindset Shifts in the Developer to CEO transition Responsibility changes how decisions feel—and how quickly they must be made Visibility and communication become part of the job Growth here isn't about changing who you are. It's about growing into what the role requires. Developer to CEO transition and evolving the agency niche over time As companies mature, the Developer to CEO transition continues through strategic evolution. Niches tighten, then expand. Focus shifts based on market feedback, strengths, and timing. The most successful agencies don't chase trends. They adjust deliberately, guided by experience rather than impulse. Developer to CEO transition: what to do earlier if you could restart Ask founders what they'd change, and many give the same answer: find peer support sooner. The Developer to CEO transition becomes clearer—and far less lonely—when you're not navigating it in isolation. This episode of the Building Better Developers podcast is a reminder that growth doesn't come from having all the answers. It comes from asking better questions, learning from others, and building momentum—one decision at a time. Stay Connected: Join the Developreneur Community We invite you to join our community and share your coding journey with us. Whether you're a seasoned developer or just starting, there's always room to learn and grow together. Contact us at info@develpreneur.com with your questions, feedback, or suggestions for future episodes. Together, let's continue exploring the exciting world of software development. Additional Resources Maintaining Momentum And Steady Progress Consistency And Momentum: Keys To Success New Year, New Momentum: What Developers Can Look Forward to in 2026 Habits, Roadmaps, and the Value of Career Momentum Building Better Foundations Podcast Videos – With Bonus Content

Over 1.5million adults in the UK tried weight loss drugs in 2024-25. Many swear by them, but they have been associated with side effects including nausea and, in some cases, extremely painful gallstones. But what does the evidence actually tell us, and what is the wider impact on the way we view our bodies in society?James Gallagher is joined by Professor of Cardiometabolic Medicine at the University of Glasgow Naveed Sattar, Dr Beverley O'Hara, Lecturer in Public Health Nutrition at Leeds Beckett University, and Dr Margaret McCartney, resident Inside Health GP. They discuss what the evidence tells us about the potential known side effects of these weight loss drugs, and the potential impact their use has on our view of obesity as a society. We also hear from Sarah Le Brocq, who has struggled with obesity all her adult life and has been on these drugs for the past 2-3 years about her experiences. Margaret McCartney has no conflicts of interest to declare.Beverley O'Hara has no conflicts of interest to declare. She has 2 roles with the Association for the Study of Obesity (voluntary academic positions).Naveed Sattar has consulted for and/or received speaker honoraria from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gan & Lee, GlaxoSmithKline, Hanmi Pharmaceuticals, Kailera, Mass Medicines, Menarini-Ricerche, Metsera, Novo Nordisk, Pfizer, Regeneron, Roche, UCB Pharma, and Verdiva Bio; and received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche.Presenter: James Gallagher Producer: Hannah Fisher Researcher: Tom Hunt Production coordinator: Stuart Laws Content Editor: Ilan Goodman

Max Martina on Mastering Adaptive Leadership for Complex Challenges in Modern Business Cambridge-leadership.com About the Guest(s): Max Martina is an accomplished leader in the field of change leadership, currently serving as the President of Cambridge Leadership Associates, a prominent consultancy founded at Harvard’s Kennedy School of Government. With a robust background spanning over two decades in corporate management and startups, Max is also a partner at the executive advisory firm Nofsinger Group. His extensive consultancy expertise encompasses working with C-suite and board-level executives across both public and private sectors, with clients including major companies such as PepsiCo, IHG, Microsoft, Pfizer, Amgen, and Intel, along with organizations like the United Nations. Max has been featured in media outlets including CNN, NPR, and MSNBC and brings a wealth of knowledge to the realm of leadership consulting. Episode Summary: In this engaging episode of the Chris Voss Show, host Chris Voss welcomes Max Martina, a distinguished leader in change leadership, to explore the current dynamics and the pressing need for adaptive leadership in today’s fast-evolving world. The conversation delves into the intricacies of adaptive leadership, contrasting traditional models and emphasizing the necessity for a flexible, behavior-focused approach to tackle complex issues within organizations. Listeners get an in-depth look at how leadership is evolving with the rapid rise of AI, economical upheavals, and global challenges. Throughout the discussion, Voss and Martina highlight the notion that leadership is not synonymous with authority and that true leaders are those who practice and exhibit flexible behaviors suited to ever-changing environments. They explore the limitations of traditional leadership dogmas, such as trait theory, and the advantages of adaptive leadership, grounded in behavior and self-awareness. Martina shares insights into how executives can foster an environment that thrives amidst uncertainty, focusing on critical areas such as diagnostics, experimentation, and the shift from individual contributors to team-based leadership. This episode is a valuable resource for anyone interested in understanding modern leadership dynamics and how to apply these principles effectively. Key Takeaways: Adaptive leadership diverges from traditional theories, focusing on flexibility and behaviors over positions of authority. The need for self-awareness and behavior change is critical for effective leadership, particularly amid today’s rapid technological advancements. Adaptive leadership emphasizes diagnostics and experimentation in solving complex, adaptive problems that cannot be addressed by technical solutions alone. Building organizational capacity involves shifting from a focus on individual execution to fostering a conducive environment that supports collective learning and problem-solving. With AI driving unprecedented changes, the necessity for adaptive leadership has become more pronounced to keep up with the escalating rate of transformation. Notable Quotes: “Leadership isn’t about having authority; it’s about practicing certain behaviors regardless of your role or title.” “We’re outpacing humanity’s ability to respond systemically to the complexity that exists, and the antidote is leadership.” “Change isn’t hard, but adapting to the losses that change brings is what challenges us the most.” “Successful leadership requires diagnostics – understanding the source of the problem and the stakeholders involved.” “Organizations today need leaders who can not only solve problems but are curious enough to experiment and find new solutions.”

Gregory Zuckerman describes the climactic moment vaccine results arrived, with Pfizer and Moderna reporting high efficacy, while Novavax and AstraZeneca faced unique logistical and reputational challenges. 7

Send a textA newborn brain can feel the pulse before it knows the tune—and that single insight opens a door into how early our minds start to organize the world. We kick off the new season by exploring two studies that hit close to home: one revealing that infants build visual categories and detect musical rhythm far earlier than many assumed, and another mapping the real‑world challenges older adults face when caring for pets they deeply love. The data is surprising, the implications are practical, and the thread running through it all is how we turn evidence into everyday decisions.Our guest, Dr. Raven the Science Maven, brings sharp insight and contagious energy to the bigger question: how do we bridge science and public life? From molecular biology to a PhD focused on communication, from catchy vaccine tracks to hosting Pfizer's Science Will Win, Raven shows how storytelling, music, and personal narrative make complex ideas land. We talk institutional barriers, the pandemic's hard lessons, why every science degree should include communication training, and how her nonprofit, The Science Haven, sparks curiosity with projects like Stellar Dreams.If you enjoy smart, human stories that connect lab findings to daily choices, tap play, subscribe, and share with a friend who loves science and pets. And if you care about better SciComm in higher education, go to make science make sense.com and add your name. Your voice helps science reach the people it's meant to serve.Dr. Baxter's Website - you'll find her podcast link and social media links hereOur links - you'll find all of our social links and website links hereSupport the showFor Science, Empathy, and Cuteness!Being Kind is a Superpower. All our social links are here!

From Music to Medicine: Rethinking Clinical Trials, AI, and Real-World Evidence On this episode Gil and Gregg welcome Amir Lahav, MD, ScD, founder and CEO of SkyMedAI and curator of the Digital Health AI Innovation Summit in Boston. Dr. Lahav traces his unlikely path from working musician to Harvard Medical School faculty, Pfizer rare-disease innovator, and now advisor to digital health and life sciences companies. The conversation explores how music-driven neurorehabilitation helped stroke survivors regain motor function, why traditional snapshot-based clinical trials are “embarrassingly wrong” for real-world patients, and how AI and wearables can turn continuous data into earlier detection and more humane care. Lahav also warns about overconfident, under-validated AI and argues that the most successful health companies by 2030 will be those that know when not to use AI. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Few issues have tested public trust in medicine as deeply as vaccines, and few individuals have influenced that dialogue more than Dr. Paul Offit, director of the Vaccine Education Center at the Children's Hospital of Philadelphia and a longtime member of the FDA's Vaccine Advisory Committee. In this timely and candid interview with Raise the Line host Lindsey Smith, Dr. Offit points to this year's severe flu season and a resurgence of measles as alarming proof points of how a changing federal perspective on vaccine policy is having a real impact on public health. “You'd like to think you can educate about the importance of vaccines, but I fear at this point the viruses themselves are doing the educating.” In this wide ranging discussion, Dr. Offit also addresses: The rigorous and painstaking process of developing vaccines, based on his experience co-inventing the rotavirus vaccine. Shifting levels of public trust in scientific organizations. Promising innovations in vaccine development. Don't miss this deeply-informed perspective on the interplay of science, policy, and public education, and his encouraging message to young clinicians about managing the current challenges in public health.  Mentioned in this episode: Vaccine Education Center at Children's Hospital of PhiladelphiaPerelman School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Dr. Monty Pal and Dr. Ari Rosenberg discuss the evolution of treatment strategies in head and neck cancers, including the challenges of treating both HPV-positive and HPV-negative disease and the emergence of blood-based biomarkers to advance personalized therapy across different subtypes. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today, we're going to explore the evolving landscape of treatment strategies in head and neck cancer management, including locoregionally advanced head and neck squamous cell carcinoma, which happens to be on the rise in United States, in part due to spike in HPV-mediated oropharyngeal cancers. We're also going to discuss the emerging strategies of using blood-based biomarkers to really advance personalized therapy. Joining me for this discussion is Dr. Ari Rosenberg. He's a medical oncologist focused on head and neck cancer, and he's an associate professor – congratulations on the recent promotion – at the University of Chicago. The University of Chicago has really produced luminaries in this field, Dr. Rosenberg included. I've had the pleasure of getting to know Dr. Ezra Cohen over the years, who really had his grounding there, and of course Everett Vokes, former ASCO President. I'm really looking forward to this conversation, Ari. Thanks so much for joining us. Dr. Ari Rosenberg: Thanks, Monty. Thanks for the invitation. Dr. Monty Pal: You got it. And just a quick note for our listeners, our full disclosures are going to be in the transcript at the end of this episode. So let's start with the basics, if you don't mind. So, head and neck cancers are very diverse and they're challenging, right? In the sense that they're near vital organs, the treatments, you know, as we all saw during fellowship, if not now in clinical practice. They can really have such a major impact on vital organ function, speech, swallowing, et cetera. Can you just comment on head and neck cancers that are on the rise in the U.S.? I alluded to this briefly. Particularly, we've heard this in the context of colorectal cancer and so forth. Are you actually seeing younger adults being affected by this? Dr. Ari Rosenberg: Yeah, thanks for that. The vast majority of head and neck cancers are head and neck squamous cell carcinomas, as I'm sure many of the listeners recall as well from fellowship or their current training. And as you alluded to, the organ function, long-term and functional quality of life outcomes are quite important, particularly in the context that these develop in high value real estate, parts of our head and neck area that we use for speaking, swallowing, all sorts of other essential functions as well. As you also alluded to, we think of this in two different particular subtypes of head and neck cancer. The historical head and neck cancer from 50, 60 years ago was almost exclusively related to carcinogen exposure, tobacco, alcohol use, and that subtype of carcinogen-induced head and neck cancer has been slowly declining. However, over the last now several decades, we've been seeing an increase in primary oropharyngeal squamous cell carcinoma, mostly tonsil, base of tongue. These are attributable to HPV, human papillomavirus exposure. And that's now the majority of the head and neck cancers that we tend to see in our clinic. As you also alluded to, these have very different prognoses as well. HPV-related head and neck cancer has a much more favorable prognosis where much of the interest has been in can we de-intensify to optimize long-term function? But then the non-HPV-related head and neck cancer, or what we call HPV-negative head and neck cancer, continue to be very, very challenging. We only managed to cure about half of these folks, with many of these patients developing the current disease. These patients, in addition to being difficult to treat, also have major impacts both in terms of the treatments they undergo as well as their disease that can impact their function and quality of life. And you hinted at this a little bit, but we have been seeing an increase in younger patients with HPV-negative head and neck cancer as well, which is quite concerning. Younger patients, oftentimes never smokers, never drinkers, who are developing non-HPV-negative head and neck cancer. And that's been a little bit of a more recent trend that we've been seeing as well. So, definitely a lot of work to be done to optimize and improve outcomes across all of these different head and neck cancer subtypes. Dr. Monty Pal: I mean, I'm just curious, you know, in the context of colorectal cancer, one of the things that we talk about is the potential role of the microbiome driving some of these young-onset cancers with, you know, perhaps there being an impact on, for instance, inflammation and the gut and what have you. Tell me about head and neck cancer. Is this anything known as to why younger patients might be getting diagnosed with non-HPV type cancers? It's odd to me. Dr. Ari Rosenberg: Yeah, it's a great question. A lot of people are working on it. I think we folks have hypotheses, but it hasn't totally panned out exactly what's going on there. It does have a little bit more of a tendency towards women, whereas historically head and neck cancer is much more common in men than it is in women. But lots of people working on that, whether it's related to chronic inflammation, whether it's related to the microbiome. Whether it's related to dental exposure, dental work. So, a lot of folks trying to parse that out because I agree with you, it needs to be identified alongside improving treatment paradigms for these patients, the young ones and the older patients as well. Dr. Monty Pal: Interesting, interesting. You know, one of the phenomena that was sort of coming around when I was in training 25 years ago was this role of sort of induction therapy for head and neck cancers. And of course, it's really come full circle now to include checkpoint inhibitors and so forth. Tell me a little bit about this and how you apply it, maybe in an HPV-mediated context, maybe in a non-HPV context. Dr. Ari Rosenberg: Yeah, absolutely. Induction chemotherapy, as you alluded to, or neoadjuvant chemotherapy, depending on what the locoregional treatment approach is. Similar to other cancer types where systemic control early on has many potential advantages in this setting. Now, in head and neck cancer, even though induction chemotherapy is quite active in head and neck cancer, both HPV-positive and HPV-negative with pretty good response rates. A survival advantage for all comers with local regionally advanced disease remains unproven. There's been two randomized trials, both underpowered, but essentially did not show a survival advantage, showing that induction chemotherapy for all patients with locoregionally advanced and neck cancer can't be justified for a survival advantage. That being said though, there remains a number of potential advantages of giving induction or neoadjuvant chemotherapy, of course, improving systemic control and debulking the disease early on has potential advantages, and predicting the responsiveness to subsequent radiation treatment. We know for some time in head and neck cancer that the percentage of shrinkage or the response to induction chemotherapy actually predicts outcome related to radiation as a dynamic biomarker where response can be used to select patients, for example, for de-escalated radiation has been an area of active investigation, active research. And it also remains a key opportunity to evaluate predictive biomarkers and understanding pre and post treatment to better understand the biology. I'll just add to your question that recently over this past year, we also saw phase 3 data for neoadjuvant immunotherapy for a subset of head and neck cancer that is surgically resectable. And so that's reintroducing the potential benefit in the immunotherapy era of incorporating immunotherapy in the neoadjuvant or the induction setting as part of the evolving treatment paradigm for these diseases. Dr. Monty Pal: That's really interesting. And you kind of alluded to already several topics that I plan to hit on, you know, for instance, the role of immune checkpoint inhibitors, induction, chemotherapy, and so forth. And you started to touch on biomarkers. And of course, I think that's something near and dear to many of us in academic oncology. One thing that we've started talking a lot about in the context of colorectal cancer is circulating tumor DNA. How do you think this might fit in the context of head and neck cancer? Can you give us a flavor for that? Dr. Ari Rosenberg: Yeah, absolutely. In head and neck cancer, the current landscape is most developed for circulating tumor DNA for HPV-related head and neck cancer. The advantage of HPV-related head neck cancer is that you have a distinctive HPV DNA that does tend to spill out into the peripheral blood and can be detected using various different blood-based assays. And because of that advantage as a tissue agnostic approach, it turns out that a number of HPV DNA plasma assays are actually quite sensitive and quite specific. And a number of them have indeed been commercialized. Of course, not only for detecting a baseline, but also grading responsiveness during treatment and probably most importantly in the post-treatment surveillance setting, the detection of HPV DNA in the plasma remains a very important and substantial predictor of developing recurrent disease. There's been a number of trials that have been emerging looking at ctDNA and HPV-related head and neck cancer, using it, for example, as a strategy to deescalate patients. That was something we saw this past ASCO from the Dana-Farber group, and also using it to early detect recurrence and potentially intervene earlier for patients with minimal residual disease positivity. So, that remains evolving and as many folks are, I think, already using it in the clinic. But ctDNA also has a lot of potential for HPV-negative head and neck cancer. This is actually a bit more challenging to develop because you don't have that HPV DNA that you can track predictably because the tumor is an HPV- negative disease are much more heterogeneous, but there are a number of data that are coming out both for personalized assays such as Signatera or some of the other assays that require tumor. Unlike colon cancer, which you referenced, where most patients get surgery upfront, in head and neck cancer, many of the patients receive non-surgical pre-chemoradiation. So sometimes the amount of tumor available to generate a personalized assay is more limited and can be one of the challenges that we see in head neck cancer. But certainly that also seems to be emerging. And there's also further assays that are being developed for HPV-negative head neck cancers, such as methylomic signatures and others that may be tissue informed or tissue agnostic. And these are also emerging, particularly in the post-treatment surveillance setting as strong predictors of recurrent disease. So while we're certainly behind some of these other more common tumor types, colon cancer, lung cancer, we're right there with them and more and more trials are going report out, including a number of trials in our upcoming [University of Chicago] Head and Neck Cancer Symposium where I'll be presenting some data and others in the field will be presenting some data looking at ctDNA both for HPV-positive and for HPV- negative to try to improve outcomes for these patients. Dr. Monty Pal: That's so interesting. I've got to tell you that in kidney cancer, what I deal with day to day is a very low shedding disease, right? So techniques as opposed to ctDNA looking for tumor-informed information, that might be less preferred to something like methylomics where you might not necessarily be so contingent on what's happening in the primary tumor. I'm really interested in you mentioning that. Just a point of clarification, this is something I'm trying to wrap my head around. You'd mentioned circulating tumor HPV DNA, right? I assume this is markedly different from just looking for HPV titers in the patient, right? So is this actually incorporated elements of HPV within, you know, essentially host genome, if you will? Dr. Ari Rosenberg: Yeah, correct. This is circulating tumor HPV DNA. And we think of it biologically as a plasma-based tumor DNA biomarker that's specific for HPV-related head and neck cancers. Dr. Monty Pal: Got it, got it. It makes me wonder whether or not this might be applicable to diseases like cervical cancer and so forth where there's also extensively, you know, biology driven by HPV. Is that fair? Dr. Ari Rosenberg: Yes, definitely. And in the head and neck cancer field, much of this ctDNA actually was derived from a different viral mediated head neck cancer, is less common in the U.S., but nasopharyngeal cancer, which is oftentimes associated with EBV. That has been a biomarker for quite some time in nasopharyngeal cancer. Of course, in places where EBV-associated nasopharyngeal cancer, is endemic, such as East Asia, this has been around for quite some time, but we've been using that in the U.S., and there's been trials that have used EBV DNA plasma to predict recurrence and stratify for adjuvant treatment, for example. And so now with HPV, it's much more applicable to our US population because the vast majority of our head and neck cancer patients that we see in the US that are viral mediated in the US tend to be HPV-related. So having assays that we can use to improve outcomes for that biological subset remains of particular interest for us. Dr. Monty Pal: Yeah, that's fascinating. By the way, for the fellows listening, there's tons of boards pearls here that Dr. Rosenberg shared, EBV-associated cancers, the role of HPV and treatment association. So if you're recertifying anytime soon, I definitely think there's notes to take from this conversation indeed. I wanted to shift gears a little bit. And obviously, you're a prolific researcher. I don't think anyone goes through their fellowship in medical oncology without recounting these experiences of our head and neck patients really suffering from treatment-related toxicities. It's a real challenge. And I'm just wondering, I know a big body of work that you're focused on is really using multimodality treatment paradigms to perhaps reduce the cumulative treatment burden of patients with head and neck cancers. Can you talk about that a little bit? Dr. Ari Rosenberg: Yeah, definitely. Thanks for the question. And before I start going into some of the strategies, I'll just say that head and neck cancer, this is particularly for the fellows that are listening as well, just in reference to your prior comment, that this is really a multidisciplinary disease. At our center, all head and neck cancer patients are seen upfront at that first visit by all three specialties, med onc, rad onc, and surgery, because the choice and sequencing of modalities to optimize not only survival, but also functional quality of life outcome is so critical. And I think that's probably the biggest takeaway for anyone who treats a lot of head and neck cancer or will be treating a lot of head and neck cancer in the clinic. But in terms of more specific attempts at trying to optimize some of those parameters that you described, we really think about these separately in terms of HPV-positive and HPV-negative head and neck cancer. For HPV-positive head and neck cancer, the cure rates are quite high with chemo radiation, although not for everyone. There's still about 15, 10 to 15 % of folks that will develop a recurrence. But for the vast majority of patients, standard chemoradiation is quite a cure to therapy, but the toxicity associated with that can be quite substantial. And so there's been a number of attempts to try to deescalate treatment. It turns out that deescalating everyone with locoregionally advanced HPV-positive head and neck cancer is not a good strategy because it's not able to select out the patients that really do need full dose treatment. And we have seen some negative trials that show inferior outcomes when everyone is deescalated. But what does remain promising is again, trying to select out who the best candidates are for deescalated treatment. The folks at MSK have hypoxia imaging that they're using in trials that looks quite promising to select for the more favorable deescalatable biology. At our center, we've been interested in using induction chemotherapy to stratify response and select patients for deescalated treatment with excellent survival outcomes and reduce toxicity with deescalated treatment. And more recently, ctDNA that us and other groups, such as the Dana-Farber group, is using. And that also looks quite promising. Again, how do you select the patient who will do well with less radiation versus the ones that really need the full doses and volumes of radiation? And then for HPV-negative head and neck cancer, this is a much trickier disease because already the survival outcomes are not like we want it to be. Trying to figure out how to improve survival outcomes remains an important thing. Using immunotherapy seems to be one of the key cornerstones to that. But these are patients that also suffer from a lot of toxicity related to their treatment. We completed a trial not too long ago that we published this past year where we, in HPV-negative head and neck cancer patients, de-intensified the radiation for responders to neoadjuvant chemoimmunotherapy. And those patients did similar, if not even a little bit better, than the non-responders who got full dose treatment. So something that does warrant further investigation as well. How do we not only improve survival for those patients, but also reduce some of the long-term toxicities? Dr. Monty Pal: This is brilliant. I'm taking so many notes as you were mentioning these items. There are so many areas where I think the research crosses over. I already mentioned, know, ctDNA, for instance, and metabolomics and the places where that might apply to kidney cancer. The hypoxia imaging really caught my ear too. Obviously, kidney cancer is disease highly predicated on hypoxia. So thank you for all of this. We've got about a minute or so. So, I'm going to ask you for a really tall task here. Can you tell us what you foresee being some of the biggest challenges that sort of lie ahead and head and neck cancer. You've already kind of alluded to it with ongoing research, but if you had to pick maybe 2, 3 problems, the very most that we really need to get to and head and neck cancer, what would that be? Dr. Ari Rosenberg: Yeah, that's a great question. Obviously, lots of things to be done, but if I'm going to limit it to just a couple, I would say number one is really trying to improve the survival for HPV negative local regionally advanced head and neck cancer. We talked early on about how we are seeing, you know, of course we see many of these people that were smokers and drinkers, but also seeing these in younger patients, in patients without a history of tobacco use. Some of these are very biologically aggressive and we need better treatments beyond surgery, beyond chemo radiation, beyond immunotherapy to improve outcomes for these patients and cure more of them. So, I would say that's one big area. And the other is, which we didn't speak about so much in this talk, but remains one of the biggest challenges that we see in the clinic is the recurrent metastatic head and neck cancer patients. This is an incredibly challenging disease to treat, not only with poor survival, but also with substantial impacts on quality of life and function. mean, these are bad recurrences that cause a lot of pain, functional deficits, really impacts quality of life as well. So developing novel therapies, many of which are currently in clinical trials and many of which are currently continuing to be developed, remains so critical. How do we develop better systemic therapies, better targeted therapies, better biomarkers for recurrent metastatic head neck cancer to improve their survival and quality of life and functional outcomes. Those are the two big areas that require the most work at this time within the head and neck cancer field. Dr. Monty Pal: That's brilliant. I mean, I have to tell you I could probably talk to you all day about this, such a fascinating topic. It's a very exciting time in the field. Thank you, Dr. Rosenberg, for all your incredible contributions and thanks for sharing with us your insights on the ASCO Daily News Podcast. Dr. Ari Rosenberg: Yeah, and thanks for the introduction. Hope to do it again soon. Dr. Monty Pal: And many thanks to our listeners for your time today. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. More on today's speakers:      Dr. Monty Pal   @montypal  Dr. Ari Rosenberg @AriRosenbergMD Follow ASCO on social media:           ASCO on X     ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Monty Pal:       Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview      Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical      Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Ari Rosenberg:     Stock and Other Ownership Interests: Privo Technologies Consulting or Advisory Role: Nanobiotix, EMD Serono, Vaccitech, Novartis, Eisai, Astellas Pharma, Regeneron, RAPT Therapeutics, Geovax Labs, Janssen, Summit Therapeutics Speakers' Bureau: Coherus Biosciences Research Funding (Inst.): Hookipa Biotech, EMD Serono, Purple Biotech, Bristol-Myers Squibb/Celgene, BeiGene, Abbvie, Astellas Pharma, Pfizer, Janux Therapeutics

This week we chat with Jason Feifer! Jason is the Editor in Chief of Entrepreneur Magazine, where he's spent nearly a decade studying and telling the stories of the world's most successful entrepreneurs. He's also a startup advisor, keynote speaker, and a nonstop optimism machine.He's the author of the best-selling book Build For Tomorrow, host of the hit podcast Help Wanted with over one million monthly downloads, and the writer of the weekly newsletter One Thing Better, read by more than 70,000 leaders. LinkedIn has named him a Top Voice in Entrepreneurship.Beyond media, Jason is the cofounder of CPG Fast Track, Chief Content Officer for the business community Uncharted, and a trusted advisor to startups. He's delivered keynotes for global brands like Google, Microsoft, Pfizer, and Alibaba—helping teams turn adaptability into a competitive advantage.And above all, Jason is a husband and proud father of two, bringing heart and clarity to everything he builds.✨ This episode is presented by Brex.Brex: brex.com/trailblazerspodThis episode is supported by RocketReach, Gusto, OpenPhone & Athena.RocketReach: rocketreach.co/trailblazersGusto: gusto.com/trailblazersQuo: Quo.com/trailblazersAthena: athenago.me/Erica-WengerFollow Us!Jason Feifer: @heyfeifer@thetrailblazerspod: Instagram, YouTube, TikTokErica Wenger: @erica_wenger

Medical training is still stuck in the arcade era: expensive, basement-bound simulators and outdated software that rarely capture the real stakes of clinical decision-making. In this episode, host Alexandra Takei, Studio Director at Ruckus Games, sits down with Sam Glassenberg, founder of Level Ex (now part of Relevate Health), to unpack how game developers can modernize healthcare learning by truly embracing the craft of video game design, not “gamification” lipstick. The opportunity and the market here are much bigger than you might assume. Healthcare is a trillion-dollar industry in the US alone, and if you can create products that save the medical system money while also growing the $200B video game industry, that's a win-win. The conversation explores why even mediocre games outperform traditional training (the bar is shockingly low), and how live-ops principles let teams update clinical guidance fast. The pair also discusses who plays these games, and it turns out that it's not only doctors but “normal people” who have found these games on the app store. They go deep on design: mapping real clinical challenges to proven genres (diagnosis as reductive-reasoning puzzles, ventilators as rhythm games), and why domain experts often describe what's hard for residents, not what triggers adrenaline for experts, which is the source of “fun” in games. Finally, Sam breaks down the business: sponsored content by clients like Pfizer and Merck, free-to-play for doctors gameplay, and playable ads. We'd also like to thank Overwolf for making this episode possible! Whether you're a gamer, creator, or game studio, Overwolf is the ultimate destination for integrating UGC in games! You can check out all Overwolf has to offer at https://www.overwolf.com/.If you like the episode, please help others find us by leaving a 5-star rating or review! And if you have any comments, requests, or feedback shoot us a note at podcast@naavik.co. Watch the episode: YouTube ChannelFor more episodes and details: Podcast WebsiteFree newsletter: Naavik DigestFollow us: Twitter | LinkedIn | WebsiteSound design by Gavin Mc Cabe.

On her first day as CFO at Greenphire, Sue Vestri sat in a conference room “learning all of the acronyms” of the clinical trial industry, she tells us. There were “many, many, many,” she recalls, and she listened to the sales team outside her door to understand how the product was positioned and why it mattered.That willingness to learn from the ground up defines her career. Earlier, a mentor warned her she would stagnate if she stayed in the safety of a large company. “You've got to go to grow,” he told her. She left for a 100-employee cloud software firm, a decision that launched a string of growth-company chapters, transactions, and ultimately multiple CFO seats.At Greenphire, she joined when the company had roughly 72 employees and “very low double digit revenue,” she tells us. Under private equity ownership, it expanded globally, shifted from clinical sites to big pharma customers, and supported the Pfizer clinical trial during COVID. Sue and her CEO conducted “20 or 30 presentations” during a remote exit process, she tells us.Today, as CFO of CRIO, she describes finance as embedded in the business—not “sitting behind a desk… producing financial statements.” Her filter for AI is deliberate: avoid the “shiny object” and invest in what is “truly transformational,” she explains. Whether evaluating predictive revenue indicators or AI tools, Sue's throughline remains the same—grow, but with discipline.

Incogni advertisementUse code “https://nordvpn.com/earthancients at the link below to get an exclusive 60% off an anual Incogni plan.Your URL is: https://incogni.com/earthancientsMichael J. Menard: Greater Than Gravity, How Childhood Trauma is Pulling Down HumanityWhat if America's #3 leading cause of death has been hiding in plain sight?In Greater Than Gravity, Michael Menard exposes a devastating truth that will shock the world: Childhood trauma is killing 889 Americans every day—more than accidents, strokes, and diabetes combined. Yet it doesn't appear on any official cause-of-death list because we've been counting the bodies wrong.When someone with severe childhood trauma dies of a "heart attack" at 55 instead of 75, we call it heart disease. When they overdose, it's addiction. When they take their own life, it's suicide. But strip away the medical terminology and you see the truth: these are trauma deaths, pure and simple."This is the largest threat to the well-being of humanity known today." —Dr. Glenn Schiraldi, world-renowned trauma expertAfter building a corporate empire and creating fourteen revolutionary patents, Menard made a discovery that stopped him cold. While writing his memoir about growing up with thirteen siblings, he realized their "tough childhood" was actually complex trauma. Its deadly fingerprints were everywhere—two brothers lost to addiction, his family stalked by depression, and invisible wounds that bled across generations.His engineer's mind couldn't let it go.What he uncovered will change everything: Childhood Trauma is the #1 cause of addiction, suicide and incarceration. 89% of teen suicide attempts trace to childhood trauma. 85-100% of addiction patients have trauma histories. 90% of prisoners carry childhood scars. The $14 trillion annual cost exceeds our entire defense budget. We've been treating symptoms while the real epidemic claims nearly 900 lives daily.But here's what no one saw coming: The very force pulling humanity down could become the force that lifts us up.Greater Than Gravity isn't just a book—it's the battle cry that breaks the silence on America's hidden killer. Through his foundation UACT, Menard presents the first comprehensive plan to end childhood trauma entirely. Not reduce it. Not manage it. END IT. The 889 daily deaths we could prevent. The lives we could heal. The future we could change.It all starts with opening this book.Labeled as "non college bound" he was placed in a trade school program. At the age of twenty-one Michael Menard joined Johnson & Johnson to operate the blueprint machine. Twenty-five years later he was named the company's first VP of engineering and an officer of the company with responsibilities in forty-four countries. Now labeled as "exemplary creator", he has received fourteen US and multiple international patents, including the inventions of infant disposable diapers with elastic legs and sanitary napkins with wings for women.As co-founder and president of The GenSight Group, a company helping corporations find a systematic approach to strategic choice and resource optimization, Michael has advised senior leadership at institutions such as Fedex, Westinghouse, Cisco, Glaxo, Pfizer, Coca-Cola, and the US Department of Energy. Michael has contributed to numerous professional publications including Harvard Management Update, Gartner Research, and The Journal of the American Management Association.https://www.michaeljmenard.com/aboutBecome a supporter of this podcast: https://www.spreaker.com/podcast/earth-ancients--2790919/support.

The latest episode of Tin Foil Hat features Justin Leslie discussing his work on Pfizer's mRNA vaccine platform, why he became a whistleblower, and his views on true health, the terrain model, and virology. He shares insider perspectives on Project Veritas, Project Whistleblower, and investigations into alternative media figures, raising questions about transparency and controlled opposition. The episode also explores media manipulation, medical ethics, bodily autonomy, and alternative health models beyond Big Pharma. Please subscribe to the new Tin Foil Hat youtube channel:  https://www.youtube.com/@TinFoilHatYoutube Grab your copy of the 2nd issue of the Chaos Twins now and join the Army Of Chaos: https://bit.ly/415fDfY Check out Sam "DoomScrollin with Sam Tripoli and Midnight Mike" Every Tuesday At 4pm pst on Youtube, X Twitter, Rumble and Rokfin! Join the WolfPack at Wise Wolf Gold and Silver and start hedging your financial position by investing in precious metals now! Go to https://www.samtripoli.gold/ and use the promo code "TinFoil" and we thank Tony for supporting our show. CopyMyCrypto.com: The 'Copy my Crypto' membership site shows you the coins that the youtuber 'James McMahon' personally holds - and allows you to copy him. So if you'd like to join the 1300 members who copy James, then stop what you're doing and head over to: https://copymycrypto.com/tinfoilhat/ You'll not only find proof of everything I've said - but my listeners get full access for just $1 LiveLongerFormula.com: Check out https://www.livelongerformula.com/sam — Christian is a longevity author and functional health expert who helps you fix your gut, detox, boost testosterone, and sleep better so you can thrive, not just survive. Watch his free masterclass on the 7 Deadly Health Fads, and if it clicks, book a free Metabolic Function Assessment to get to the root of your health issues. Grab Tickets To Sam Tripoli's Live Shows At SamTripoli.com: Hollywood, CA: 2/10 Perryville, MD: 2/20 Pottstown, PA: 2/21 Las Vegas, NV: 2/28 Bakersfield, CA: 3/6 Yuma, AZ: 3/7 Hollywood, CA: 3/10 Batavia, IL: 3/26-3/28 Toronto, CA: 4/17-18 Dallas, TX: 4/24 Fort Worth, TX: 4/25 Albuquerque, NM: 6/12-6/13 Lawerence, KS: 9/17-9/19 Tulsa, OK: 10/9-10/10   Please check out Justin Leslie's internet:  Website: https://justintegrity.net Rumble: https://rumble.com/c/justintegrity Twitter: https://x.com/justintegrityy Instagram: https://www.instagram.com/justin.leslie3/ Youtube: https://www.youtube.com/@JustIntegrityNetwork   Please check out Sam Tripoli's internet: Linktree: https://linktr.ee/samtripoli Sam Tripoli's Stand Up Youtube Page: https://www.youtube.com/@SamTripoliComedy  Sam Tripoli's Comedy Instagram: https://www.instagram.com/samtripolicomedy/%20P Sam Tripoli's Podcast Clip Instagram: https://www.instagram.com/samtripolispodcastclips/   Please support our sponsors: ShipStation: Try ShipStation free for sixty days with Full access to all features, No credit card needed! Go to Ship Station dot com  and use code tinfoil for sixty  days for free! Sixty days gives you plenty of time to see exactly how much time and money you're saving on every shipment.That's Ship Station dot com code tinfoil. Ship Station dot com code tinfoil. QUO: Quo is the #1-rated business phone system on G2 with over 3,000 reviews, trusted by more than 90,000 businesses to stay connected and professional. Calls, texts, voicemails, transcripts, and contacts all live in one clean view, giving your team full context and faster communication. Make this the year no opportunity slips away. Try Quo for free and get 20% off your first six months at Quo dot com slash TINFOIL. That's Q-U-O dot com slash TINFOIL. Quo — no missed calls, no missed customers.